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Wilms

tumor,

a

childhood

tumor

arising

from

undifferentiated

renal

mesenchyme, is diagnosed in North America at a frequency of 1 in 10,000 live births
and accounts for 5% of all pediatric cancers. The etiology of Wilms tumor is
heterogeneous with multiple genes known to have an effect on Wilms tumor
development; however, these genes are rarely associated with familial Wilms tumor.
Gene mutations in WT1, WTX, CTNNB1 and TP53 are observed in a third of sporadic
tumors, while the causative gene(s) responsible for familial Wilms tumor are largely
unknown. Approximately 2% of Wilms tumor patients have a family history of Wilms
tumor. Familial predisposition is inherited in an autosomal dominant manner and
demonstrates incomplete penetrance, estimated to be 30%.
Whole genome sequencing of eleven individuals in three Wilms tumor families
was performed to identify the gene(s) responsible for genetic predisposition to Wilms
tumor in these families, and to increase our understanding of a genetically
heterogeneous cancer.

Variant calling was performed by GATK, FamSeq and

CASAVA to detect single nucleotide variations (SNVs), insertions/deletions (indels)
and structural variants. Shared variants within each family were identified and
prioritized based on expression in fetal kidney, minor allele frequency less than 1%,
and the predicted functional significance of the alteration on protein structure.
!
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Candidate mutations were then assessed in each family for cosegregation with the
affected/obligate carrier status. To examine the sequence integrity and frequency of
candidate gene mutations in Wilms tumor, a comprehensive mutation analysis of each
candidate gene, including Sanger sequencing of the entire coding region and
quantitative PCR (qPCR) to detect exonic insertions/deletions, was performed using
genomic DNA from 47 additional Wilms tumor families and tumor DNA from 175
sporadic Wilms tumors. As a result, a recurrent 570kb germline duplication including
NBAS, DDX1, MYCN and MYCNOS was identified in 4% of families, as well as
germline missense mutations in DICER1 (4% of families) and SPHK2. Functional
studies demonstrate that the missense mutation identified in SPHK2 does not have an
effect on apoptosis or proliferation, but instead alters SPHK2 subcellular localization
and expression of target genes.
Our analysis resulted in the successful identification of Wilms tumor
predisposition genes in each family, and provided support for the involvement of
DICER1 and DDX1/MYCN in Wilms tumor development. Additionally, our
identification of SPHK2 as the 19q familial Wilms tumor predisposition gene has
opened up new avenues of research into the role of sphingolipid signaling in
nephrogenesis and cancer development. Significantly, the communication of these
results directly to patients within each family allows for the continued monitoring of
new family members for the potential early detection of not only Wilms tumor, but
other phenotypes associated with the specific gene mutations.
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Chapter 1. INTRODUCTION
1.1.

Understanding Wilms tumor biology
Wilms tumor is an embryonal renal malignancy that is predominately

diagnosed in children before 10 years of age.1 It is the most common pediatric kidney
cancer, occurring in 1 in 10,000 live births in North America. Unilateral cases
represent 90-95% of Wilms tumor diagnoses and have a mean age of diagnosis
occurring around 43 months. Bilateral cases are usually diagnosed at 33-38 months.1
It was this kidney malignancy, in addition to neuroblastoma and retinoblastoma, which
constituted the three tumor types studied in the establishment of the “two-hit” model of
tumor suppression.2 Although the survival rate for Wilms tumor is over 90% for
confined disease, the development of secondary malignancies due to current therapy
is common. Thus, identification of the genes and molecular pathways driving Wilms
tumorigenesis is critical for 1) our understanding of the biology of Wilms tumor and
other embryonal tumors, and 2) the development of targeted therapies aimed at
reducing cancer mortality, while concurrently eliminating harmful side effects.
Wilms tumor is thought to originate from pluripotent embryonic renal progenitor
cells that are unable to differentiate normally. Although the majority arise sporadically,
roughly 2% of patients have a family history of Wilms tumor. In these instances, an
earlier age of diagnosis and increased prevalence of bilateral tumors is typically
observed, although this varies between families.1-4 Until recently, the genetic etiology
of most cases of non-syndromic Wilms tumor has remained a mystery, as traditional
candidate gene approaches have been inefficient in revealing causal elements of this
genetically heterogeneous cancer. High-throughput next-generation sequencing has
represented a turning point in the identification of disease genes with the ability to
!
!
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screen large numbers of genes simultaneously in an unbiased manner. Using this
technology, surveying the genetic landscape of Wilms tumor has just begun to unravel
the mutation events responsible for both sporadic and familial cases. However, the
identification of “Wilms tumor genes” is far from complete. While the genes
responsible for sporadic Wilms tumor cases are known in approximately 50% of
cases, the cause of the majority of familial Wilms tumor cases is largely unknown.

1.1.1. Kidney Development
Wilms tumors originate from undifferentiated renal mesenchyme and represent
an example of aberrant kidney development resulting in cancer. Kidney development
commences at approximately day E36 in humans (E10.5 in mice), and is the result of
complex reciprocal interactions between two tissues derived from the intermediate
mesoderm: the metanephric mesenchyme, which differentiates into stromal cells and
epithelial components of the nephron, and the ureteric bud, which gives rise to the
collecting duct system.5-6 Signals produced from the metanephric mesenchyme
induce the ureteric bud to bifurcate as it invades the mesenchyme, resulting in the
induction of mesenchyme condensation along the surface of the bud (Figure 1). A
portion of the condensed mesenchyme forms pretubular aggregates adjacent and
interior to the tips of the branching ureteric bud. These pretubular aggregates then
undergo a mesenchymal-to-epithelial transition to form the epithelia (comma- and Sshaped bodies), which later develop into the nephron.6 The stromal elements, derived
from cells of the metanephric mesenchyme that were not induced to condense and
epithelialize, develop in the periphery of the mesenchyme and between the branches

!
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Figure 1. Kidney development. Interactions between the metanephric mesenchyme
(MM) and ureteric bud (UB) result in invasion of the UB into the MM, leading to
mesenchyme condensation and formation of pretubular aggregates. These pretubular
aggregates go on to form the epithelial components (renal vesicle, comma-shaped
bodies, S-shaped bodies) of the kidney. The distal end of the S-shaped body
connects to the ureteric bud, while the proximal end joins to form the glomerulus.
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of the ureteric bud. These stromal cells include pericytes and mesangial cells. The
iterative branching of the ureteric bud yields the collecting duct system of the kidney.
This entire process kidney development is completed by week 34 in humans, and
postnatal day 7 in mice.

1.1.2. Wilms tumor resembles early kidney organogenesis
The distinctive histology of Wilms tumors is reminiscent of fetal kidney
development and suggests that Wilms tumor arises from pluripotent embryonic renal
progenitors that, instead of undergoing normal differentiation to form the functional
kidney, show arrested differentiation and aberrant proliferation, ultimately resulting in
a Wilms tumor. This is supported by a number of morphological and molecular
observations. First, the characteristic triphasic appearance of Wilms tumor is
histologically comparable to that of the developing kidney (Figure 2). Wilms tumors
frequently contain variable proportions of three cellular components derived from the
fetal mesenchyme: epithelial, blastemal, and stromal elements.8 The epithelial
elements resemble comma-shaped bodies, S-shaped bodies and glomeruli. The
blastemal component is comprised of small, densely packed cells representing
metanephric mesenchyme, while the stromal elements resemble fibroblasts, skeletal
muscle or neural elements. Moreover, gene expression studies provide further
support for a developmental-origin of Wilms tumors in that genes expressed during
early kidney development (PAX2, HOXA11, SIX1, EYA1, SALL2, MEOX1) have a
tendency to be overexpressed in Wilms tumors, while genes expressed at later stages
of nephrogenesis are downregulated in Wilms tumors.9 Additionally, genome-wide
chromatin profiling of Wilms tumors, embryonic stem cells, and normal kidney tissue
!
!
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Embryonic Kidney

Wilms tumor

Figure 2. Wilms tumor histology. Wilms tumors (right) are histologically similar to the
embryonic kidney (left). The triphasic histology of Wilms tumors shows blastemal,
epithelial, and stromal components reminiscent of fetal kidney development. However,
the tumors lack correct formation of glomeruli and nephrons.
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indicates that Wilms tumors share an epigenetic landscape with renal stem cells, with
increased domains of histone H3 lysine 4 trimethylation (K4me3) suggestive of an
open chromatin environment.10 Taken together, the histological morphology, gene
expression and chromatin profiling data imply that Wilms tumors arise from a subset
of cells arrested at an early metanephric mesenchymal stage during nephrogenesis.
Consistent with this hypothesized ontogeny, genes mutated in Wilms tumors include
those involved in directing the differentiation of early metanephric mesenchymal cells,
as well as components of signaling pathways critical for kidney morphogenesis.11

1.1.3. Nephrogenic

Rests:

the

connection

between

nephrogenesis

and

nephroblastoma
Wilms tumors are thought to arise from nephrogenic rests, which are benign
foci of undifferentiated fetal mesenchyme that, instead of fully differentiating into renal
parenchyma by 36 weeks of gestation, persists after renal embryonic development is
complete. These nephrogenic rests are found in the kidneys of 1% of infants, 30-40%
of sporadic Wilms tumor cases, and 100% of bilateral cases.12 Noninvasive follow-up
of these precursor lesions have shown they have the ability to progress, sclerose, or
regress. Two types of nephrogenic rests have been described based on their location
within the kidney. Intralobar nephrogenic rests (ILNR) are situated centrally within the
renal lobe, represent approximately 10% of nephrogenic rests, and are associated
with mutations or deletions in WT1. In contrast, perilobar nephrogenic rests (PLNR)
are located at the periphery of the renal lobe and represent 90% of nephrogenic rests.
Nephrogenic rests often share the same genetic defects found in Wilms tumors.
These shared mutations are not present in the surrounding normal kidney tissue,
!
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suggesting that they are responsible for the formation of Wilms tumor precursor
lesions in the kidney. Additional mutations only in the tumor tissue indicates that
neoplastic transformation of nephrogenic rests results in the development of Wilms
tumor.13-14

1.2.

The genetics and emergence of new genes in Wilms tumor
The etiology of Wilms tumor is heterogeneous with multiple genes known to

result in Wilms tumor formation. These genes and loci, identified through molecular
and cytogenetic analyses, have been found mutated primarily in sporadic Wilms
tumors (Table 1) and includes somatic mutations in WT1, CTNNB1, WTX, TP53,
MYCN, SIX1/2, miRNA pathway genes, and epigenetic abnormalities at 11p15.15-18
Wilms tumor is a relatively euploid cancer and, like other pediatric malignancies, the
number of somatic mutations found in tumors is low.16 This suggests that these
somatic alterations acquired by tumor cells are significant events in the initiation of
Wilms tumor.

!
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Gene
WT1
WTX
TP53
IGF2
CTNNB1
CTR9
DROSHA
DGCR8
MYCN
SIX1
SIX2

Effect of mutation
Inactivation of protein
Inactivation of protein
Inactivation of protein
Biallelic expression
Activating
Inactivation of protein
Alteration of miRNA biogenesis
Alteration of miRNA biogenesis
Activating
Activating
Activating

Somatic or Germline?
Both
Somatic
Both
Both
Somatic
Germline
Somatic
Somatic
Both
Somatic
Somatic

Table 1. Genes involved in Wilms tumor development.
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1.2.1. WT1 and CTNNB1
Wilms tumor protein 1 (WT1) was the first gene implicated in Wilms tumor
development and initially provided most of our understanding of the relationship
between kidney development and tumorigenesis. WT1, a zinc-finger transcription
factor, is essential for renal development and plays a critical role in the regulation of
expression of genes involved in nephrogenesis.19 Moreover, WT1 directs the
mesenchymal to epithelial transition of the metanephric mesenchyme through
upregulation of WNT4, leading to the differentiation of blastemal cells into mature
nephrons.20 Mutations in WT1 have been identified in approximately 20% of sporadic
Wilms tumors, and result in inactivation of the protein.15
The WNT pathway is critical for proper kidney development. Therefore, it is not
surprising that components of this signaling pathway, such as CTNBB1, have been
found to be mutated in Wilms tumors.21 Interestingly, there is a strong association
between WT1 and CTNNB1 mutations, as the majority of WT1-mutant tumors harbor
activating mutations in CTNNB1.15,22 These mutations result in stabilization of betacatenin and translocation to the nucleus where it activates downstream targets.21

1.2.2. WTX
WTX, also known as family with sequence similarity 123B (FAM123B) is
mutated in roughly 20% of sporadic tumors. Approximately 2/3 of these tumors harbor
deletions of the entire WTX gene, while the others carry missense alterations, or
nonsense and frameshift mutations resulting in a truncated protein.15,23-25 WTX acts
as a negative regulator of CTNNB1 by interacting with the beta-catenin destruction
complex in the cytoplasm to promote beta-catenin ubiquitylation and degradation.26
!
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Truncating WTX mutations identified in Wilms tumors result in the deletion of the betacatenin-binding region. As a result, beta-catenin is stabilized, accumulates in the
nucleus, and activates downstream target genes. Germline mutations in WTX,
underlying osteopathia striata with cranial sclerosis (OSCS), do not predispose to
Wilms tumors, however most children with OSCS die at an early age.27

1.2.3. TP53
TP53 is of particular importance because, although it is only mutated in a 5% of
sporadic tumors, its mutation is associated with relapse and poor prognosis due to
metastasis and resistance to therapy.28-29 The presence of anaplasia defines Wilms
tumors that have unfavorable histology and poor prognosis, and somatic TP53
mutations have been identified in ~75% of anaplastic Wilms tumors.30-31 The
mutations occur at hotspot residues or lead to truncated protein.32

1.2.4. MYCN
Approximately 10% of Wilms tumors show low-level MYCN amplification, with
no preference for histological subtypes.33-37 The increased copy number is typically
modest when compared to other tumor types which also show MYCN amplification,
such as neuroblastoma. MYCN amplification usually includes other flanking genes as
well due to their close proximity, most often DDX1, which is telomeric to MYCN.
Recurrent somatic point mutations in MYCN affecting codon 44 of the Aurora A kinase
interaction domain have recently been identified in tumors, although the significance
of these mutations is not known.16-17 It has been suggested that this recurrent
mutation has an activating function. MYCN is a transcription factor that controls
!
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expression of genes involved in proliferation and differentiation, and is critical for brain
development and essential for kidney morphogenesis.38

1.2.5. SIX1/2 mutations
Two recent studies used exome sequencing of blastemal and favorable
histology Wilms tumors to identify somatic mutations contributing to the development
of Wilms tumors. These analyses revealed a recurrent somatic hotspot mutation in
exon 1 (Q177R) of SIX1 in 10% and 7% of cases, respectively.17,32 Chromatin
immunoprecipitation sequencing (ChIP-seq) and global gene expression analysis
indicated this mutation results in the alteration of both DNA binding specificity and
subsequent gene expression profiles of downstream target genes. Additionally, the
equivalent Q177R mutation in SIX2 was also identified as a somatic change in Wilms
tumors. Expression analysis of SIX1/2-mutant tumors showed an upregulation of cellcycle and kidney developmental genes, suggestive of a renal progenitor cell state.32

1.2.6. Epigenetic alterations at 11p15
Epigenetic alterations at 11p15 are the most common alteration in Wilms tumor
cases. These defects are usually isolated, non-heritable events and typically are only
seen in sporadic cases, although not many familial tumors have been studied to date.
Loss of imprinting (LOI) or loss of heterozygosity (LOH) at 11p15 is found in most
tumors.39 A cluster of imprinted genes is located at this location. This cluster includes
IGF2, which is an embryonic growth factor, and H19, which expresses a noncoding
RNA. The H19 imprinting control region is located at 11p15 that controls expression of
IGF2 and H19. This region is differentially methylated depending on the chromosome
!
!

!

11!

parent of origin. Methylation of the maternal allele prevents CTCF binding and IGF2
expression, while H19 is actively expressed. Conversely, hypomethylation of the
paternal chromosome allows CTCF to bind, permitting IGF2 expression while blocking
H19 expression. In Wilms tumors, loss of the maternal allele and duplication of the
paternal allele by either LOH or aberrant gain of methylation at the H19-ICR results in
biallelic IGF2 expression. Biallelic IGF2 expression alone is not sufficient for Wilms
tumor development, as LOH of 11p15 was identified in the normal kidney and blood
cells of WT patients. 40

1.2.7. MicroRNA Pathway Genes
The most recent genes implicated in Wilms tumor development are those of
the miRNA biogenesis pathway. This pathway produces mature miRNAs that
negatively regulate the expression of target proteins by targeting their mRNA
transcripts. This pathway was first connected to Wilms tumor formation when
inactivating mutations in DIS3L2 were identified in Perlman syndrome.41 DIS3L2
specifically targets uridylated pre-let-7 miRNAs for degradation, and a small fraction of
patients with DIS3L2 mutations are predisposed to Wilms tumor development.
Additionally, studies have demonstrated the importance of specific miRNAs in kidney
development.42
A number of recent studies have also identified mutations in DGCR8,
DROSHA,

XPO5,

TARBP2

and

DICER1

in

Wilms

tumors.16-17,32

Somatic

heterozygous mutations in DROSHA, the most commonly mutated miRNA pathway
gene, were identified in ~12% of Wilms tumors. These were recurrent E1147K
mutations disrupting the Mg2+ binding site of the RNase IIIb domain. MicroRNA
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expression profiling demonstrated loss of the miR-200 family, whose members
include those involved in the mesenchymal-to-epithelial transition, consistent with the
pathology of the tumors. Germline and somatic mutations in DICER1 have been
identified less frequently in Wilms tumors, but appear to contribute to Wilms tumor
development through altering the balance of 5p/3p miRNAs (described in chapter 3).
1.3.

Familial Predisposition to Wilms tumor
The genes responsible for sporadic Wilms tumor cases are known in

approximately 50% of cases. However, these genes rarely contribute to instances of
familial Wilms tumor. Approximately 2% of Wilms tumor patients have an affected
relative, usually a sibling or cousin. These cases typically present at an earlier age
than sporadic Wilms tumor presumably due to the inheritance of a germline mutation
predisposing to cancer development. The majority of Wilms tumor families are small,
often containing 2-3 affected individuals. Among these affected individuals, males and
females are equally represented. Evidence suggests that the predisposition gene is
not subjected to imprinting effects, as there is no gender bias in the obligate carrier
parents of affected children. Familial Wilms tumor is also observed in a range of
ethnicities. Although most familial Wilms tumor cases are non-syndromic, there are a
minority of familial cases associated with Beckwith-Wiedeman syndrome, DenysDrash syndrome, WAGR syndrome, Perlman syndrome, and rarely, in DICER1
Syndrome.
Familial WT predisposition displays an autosomal dominant inheritance pattern
with incomplete penetrance estimated at 30%.2,43-44 Familial predisposition genes
have been localized by genetic linkage analysis to 17q12-21 (FWT1) and 19q13.3
(FWT2), although neither has been identified.45-46 The lack of linkage of some WT
!
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families to these regions indicates additional familial WT genes exist.47 This genetic
heterogeneity could be the reason for variation seen in families with respect to
penetrance, frequency of bilateral disease, and age of diagnosis. For example,
although familial Wilms tumor is typically diagnosed 12 months earlier than sporadic
cases, Wilms tumors occurring in 17q-linked families are diagnosed at a median age
of 6 years. On the other hand, families linked to chr19q show variable ages of
diagnosis, ranging from 14 to 204 months.

1.3.1. Previous Identification of familial WT predisposition Genes
With

advancements

in

next-generation

sequencing

technologies,

the

mutational landscape of Wilms tumor is becoming more clear. The overwhelming
majority of these studies, however, focused on sporadic Wilms tumors. Nonetheless,
both traditional and high-throughput sequencing efforts have contributed to a small list
of genes that, when mutated, are associated with predisposition to familial Wilms
tumor. These genes include WT1 (rarely), CTR9, DICER1, and copy number
alterations including MYCN and DDX1.
Germline mutations in WT1 are known to predispose to Wilms tumor, however
most germline WT1 mutations are frequently de novo. There are rare cases in which
germline WT1 mutations inherited from an affected or obligate carrier parent results in
familial Wilms tumor. These mutations have been reported in very few families, most
of which are small.48-51 In general, familial Wilms tumor cases are not due to germline
mutations in WT1.
Recently, next-generation sequencing technology allowed for the identification
of CTR9 as a Wilms tumor susceptibility gene. In this study, inactivating mutations in
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CTR9 were identified in 3/35 Wilms tumor families.52 CTR9 is a gene involved in RNA
Polymerase elongation by association with the PAF1 complex. Mutations in additional
members of this complex have been identified in Wilms tumor cases, providing
additional support for CTR9 as a cancer predisposition gene. Although CTR9 is a
newly established Wilms tumor predisposition gene, it should be noted that these
mutations were found in a fraction of familial Wilms tumor cases, which illustrates the
characteristic genetic heterogeneity of Wilms tumor predisposition.
The research described in this Thesis served to expand the genetic etiology of
Wilms tumor occurring in families, and successfully resulted in the identification of the
predisposing alterations in three families whose whole genomes were sequenced. We
identified germline mutations in DICER1, which have recently been found in six
families with DICER1 Syndrome-associated Wilms tumors (described in chapter 3).
Additionally, copy number alterations at chr2p24, encompassing the MYCN locus,
have recently been identified in a family with a history of nephroblastomatosis and
Wilms tumor. Our analysis resulted in the identification of two Wilms tumor families
harboring copy number alterations of this region (chapter 4). Finally, our identification
of SPHK2 as a candidate Wilms tumor predisposition gene on chr19q (chapter 2)
opens new avenues of research into the role of chromatin regulation and lipid
signaling in Wilms tumor initiation.
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1.4.

Significance
The study of Wilms tumor has generated many concepts that are fundamental

to our understanding of the genetic etiology of cancer. The first "Wilms tumor gene"
identified, WT1, plays an important role in the development of multiple organ systems
and alterations of the gene or its expression are involved in many tumor types.
Interestingly, while WT1 was originally isolated by virtue of being a "Wilms tumor
gene", it is now recognized that WT1 plays an important, although not well
understood, role in a variety of cancers, including acute lymphocytic leukemia (ALL).
Additionally, a WT1 vaccine has shown therapeutic promise against AML,
glioblastoma, breast and lung carcinoma in Phase I/II clinical trials. Thus it is very
plausible that the identification -- and the understanding of the aberrant function of -other "Wilms tumor genes" not only will represent a major step in our understanding of
cancer predisposition, but will also greatly accelerate work in the area of cancer
genetics in general and will potentially identify therapeutic targets for very common
cancers.
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Chapter 2: Whole genome sequencing to identify candidate Wilms
tumor predisposition genes

2.1.

Introduction
A number of high-throughput, massively parallel sequencing (next-generation

sequencing) platforms developed since the completion of the human genome project
has allowed for the generation of unprecedented amounts of data compared to
sequencing by capillary electrophoresis. Not only is this technology more cost
effective per base than traditional sequencing methods, but large amounts of data can
now be generated in a fraction of the time compared to conventional sequencing
approaches. Recent successes in disease gene identification using next-generation
sequencing technology has demonstrated the power of whole exome- and genome
sequencing studies to understand drivers of human disease and cancer. Fortunately,
the rapid evolution of bioinformatics analysis programs combined with the falling cost
of whole genome sequencing has allowed us to employ this technology to pinpoint
candidate genes predisposing to familial Wilms tumor.

2.2.

Illumina Whole Genome Sequencing
The Illumina sequencing platform is one of the most widely adopted next-

generation sequencers used by both research and clinical laboratories due to its low
error rates and cost efficiency. The sequencing process begins with library
preparation, in which genomic DNA is randomly fragmented followed by the ligation of
adapters to the ends of each fragment. The adapters facilitate the hybridization to an
Illumina flow cell which contains surface-bound oligos complementary to the adapter
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sequences. Here, solid-phase amplification of each single template creates clusters of
identical copies of the fragment to generate a sufficient signal for the detection of
incorporated bases. Illumina’s sequencing by synthesis approach uses a reversible
terminator method to distinguish single fluorescently-labeled deoxynucleoside
triphosphates (dNTPs) as they are incorporated into growing DNA strands. Following
the addition of a single labeled dNTP into the growing nucleic acid chain, an image is
taken to identify the incorporated base. The labeled base is then cleaved for the next
base incorporation event to take place. The nucleotide calls are distinguished from
one another based on the signal intensity measurement, resulting in the sequence of
bases from the fragment.

2.3.

Whole genome sequencing in three Wilms tumor families
To identify Wilms tumor predisposition genes, we sequenced the whole

genome of eleven individuals from three Wilms tumor families using the Illumina
sequencing platform. The individuals from each family were chosen for whole genome
sequencing based on being: 1) affected individuals or individuals known to be an
obligate carriers of the predisposing mutation by virtue of having an affected child, 2)
distantly related (to reduce the number of shared variants for further investigation),
and 3) on our already having a DNA sample from them. Informed consent was
obtained from all study participants, and approval for this research was obtained from
the Institutional Review Board at MD Anderson Cancer Center.
Illumina paired-end libraries were constructed from genomic DNA by the MD
Anderson Cancer Center Sequencing Core Facility. The advantage of paired-end
libraries is that, in addition to high quality sequence information, they also provide
!
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long-range positional

information allowing

for

the

highly precise

alignment

of sequence reads. Libraries were sequenced at approximately 30X coverage using
the Illumina HiSeq 2000 system, which is sufficient coverage to allow for the detection
of germline sequence variants. The resulting sequence data was then contained in
fastq files for processing, alignment and variant calling.

2.4.

Bioinformatic analysis
While the ability to generate larger amounts of data through next-generation

sequencing has improved exponentially, the continued development of faster, more
accurate bioinformatic analysis programs has not kept pace, resulting in a bottleneck
at the analysis stage. Additionally, there are challenges associated with identifying
rare variants to better understand the genetic basis of human diseases. Identification
of variants depends on many factors. Considerations such as coverage depth and
base quality scores have an impact on determining if an alteration is called or not, as
well as the parameters which set the threshold for variant calling. Recognizing this,
we established a collaboration with Wenyi Wang, PhD at MD Anderson, who
developed FamSeq, a computational tool that performs family-based variant calling in
next-generation sequence data. Of the eleven individuals sequenced in our study,
three individuals comprised a trio of affected parent/child and unaffected parent.
Using this family-based sequencing approach, we used information from the trio to
more accurately identify germline mutations by calculating the probability of variants
given the entire family’s raw sequence measurements. Fortunately, the data
generated from this work has not only served to advance our understanding of Wilms
tumor genetics, but also to advance a computational tool aimed at improving the
!
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identification of rare variants in family sequencing studies.
2.4.1. Read alignment and variant calling
100bp paired-end sequence reads that passed instrument QC from each
individual were processed and aligned to the GRCh37/hg19 human reference
genome using the Burrows-Wheeler Aligner (BWA) v0.5.9. PCR duplicates were
marked by Picard v1.46. Variant calls were produced using the Genome Analysis
Toolkit (GATK), FamSeq, and CASAVA, resulting in data sets which include single
nucleotide polymorphism (SNP) calls, insertions, and deletions with respect to the
reference sequence, as well as confidence scores for every covered position in the
genome. To identify copy number variation, the total number of read counts for each
position across the whole genome was extracted from the bam file. The mean read
counts for a fixed window of 50 bases was calculated and used as input for a Hidden
Markov Model (HMM) segmentation algorithm. This produced copy number segments
assigned to gains or losses depending on the ratio of total median read counts within
each segment to the mean sequencing depth across the entire genome.
2.4.2. Identification and annotation of intra-family shared variants
Using the variant calls generated by GATK, FamSeq and CASAVA, we first
compared the genotypes between the affected/obligate carrier individuals in the same
family to identify variants that are shared. These variant were contained in variant call
format (vcf) files for each individual. This analysis generated three lists of variants
specific to the three families in our study. In each family, this approach reduced the
list of putative risk alleles to those which are 1) less likely to be artifacts, and b)
presumably inherited from the same (carrier) relative. Using this approach, our
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strategy of sequencing the most distantly related affected family members and
identification of overlapping variants reduced the list of candidate variants because
the more distantly they are related, the fewer genetic variants they shared. Variants
that were not shared between family members were discarded from further
investigation, as the criteria for the predisposition gene includes the presence of the
variant within all affected/obligate carrier individuals.
Once

shared

variants

were

identified,

ANNOVAR

(http://www.openbioinformatics.org/annovar) was used to aid in the investigation of
the functional significance of variants by annotating each variant with respect to
location within the genome (intergenic, intronic, exonic, or regulatory regions) using
the annotate_variation.pl –geneanno –buildver hg19 command. Variants present in
dbSNP137 were identified using the annotate_variation.pl –dbtype snp137 command.
Variant frequencies from the 1000 Genomes database were also obtained using
ANNOVAR. Alterations were also examined for their presence in the NHLBI Exome
Variant Server (https://esp.gs.washington.edu/drupal).
Variants in exonic regions which could potentially affect protein structure
(nonsynonymous and frameshift variants) were identified and further annotated using
ANNOVAR to obtain the following scores: SIFT (annotate_variation.pl avsift),
PolyPhen

(annotate_variation.pl

ljb_pp2),

MutationTaster

(annotate_variation.pl

ljb_mt), and PhyloP (annotate_variation.pl ljb_phylop). This produced a list of variants
with predictions as to whether they are deleterious, as well as conservation scores to
assess whether identified variants occur within evolutionarily conserved regions which
could include promoter regions and sequences important for RNA expression, RNA
stability, and RNA translation.
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2.4.3. Filtering and prioritization of variants
One advantage of whole genome sequencing technology over first-generation
methods, such as Sanger sequencing, is the generation of large amounts of data with
variant calls across the entire genome. This typically results in >4 million variant calls
for each whole genome. In this current study, with whole genome sequence data from
eleven individuals, the amount of data generated required the application of a discrete
set of filters to prioritize those variants which are most likely to be the cause of
disease in the families. As previously described, we first identified intra-family shared
variants because potential Wilms tumor predisposing mutations will be those that are
present in all affected/obligate carrier individuals in a family, and absent in unaffected
family members. We then filtered these shared variants using dbSNP137 and the
1000 Genomes databases to remove variants with a minor allele frequency (MAF)
greater than 1% in those databases. This reduced a large list of potential candidate
genes by removing all variants that are commonly occurring in the general population,
with the rationale being familial Wilms tumor represents a small proportion of all
Wilms tumor cases and Wilms tumor is relatively rare in the population. Consequently,
we expected risk alleles to occur at a low frequency in the general population or to
even be novel variants. As such, variants with a MAF greater than 1% and present in
these databases were excluded from our initial analysis. Although we prioritized
variants based on their presence in dbSNP, it is important to note that pathogenic
variants have previously been included in dbSNP. With this in mind, our initial analysis
included only those variants not present in dbSNP, although the comprehensive list of
variants was archived for future examination should we be unsuccessful in identifying
a promising candidate variant.
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In order to identify the familial Wilms tumor predisposition mutation in each
family, the variants were then screened by function and embryonic expression
pattern. Similar approaches taken by other studies have proven effective in filtering
out non-causal mutations. Previous studies have shown that most alleles that are
known to underlie Mendelian disorders disrupt protein-coding sequences. Therefore,
mutations of high interest (“first tier variants”) included those that have an effect on
protein via non-synonymous mutations, insertions or deletions in a coding region.
“Second tier” variants included those that occur outside the coding region of genes
(intronic, intergenic regions). These second tier variants were saved for future
evaluation in the case that promising first tier variants were not identified. In addition,
higher priority was assigned to genes expressed in fetal kidney, as Wilms tumor is a
cancer involving fetal renal development.
The resulting data was initially assessed for variants that occurred in more than
one of the three families or that affected the same gene/functional element in more
than one family. However, this analysis failed to identify variants in the same gene
from all three families. We next shifted our analysis to variants from each individual
family (described in more detail in chapters 3-5). Following the identification of
candidate predisposition genes, the application of a co-segregation analysis was used
to further prioritize the set of key functional variants. This was because familial Wilms
tumor is rare among Wilms tumor cases, and the chance that both parents of an
affected familial Wilms tumor patient carry the predisposing mutation is unlikely. The
results from this analysis are described in the following three chapters.
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CHAPTER 3: Identification of sphingosine kinase 2 (SPHK2) as a
putative 19q familial Wilms tumor predisposition gene.
3.1.

INTRODUCTION
Following a genetic linkage analysis of a large multigenerational WT family, a

3.4Mb region of chr19q13 was identified as the location of a gene which predisposes
to familial Wilms tumor.46 Traditional approaches (i.e. Sanger sequencing) to isolate
the causal 19q familial Wilms tumor are not practical due to the number of genes
(~137) within the linked region. Fortunately, advancements in next-generation
sequencing technologies have allowed for the cost-efficient, high throughput
sequencing of individuals within the family to identify the predisposition alteration.
Using whole genome sequencing, the entire genetic landscape of six individuals
within the family was surveyed to pinpoint the predisposing alteration in the family.
This resulted in the identification of sphingosine kinase 2 (SPHK2), an enzyme
involved in the production of sphingosine 1-phosphate, as a putative 19q familial
Wilms tumor predisposition gene.

3.1.1. S1P signaling
Sphingosine 1-phosphate (S1P), a bioactive phospholipid, has emerged as an
important regulator of many fundamental cellular processes.53 In particular, S1P has
received considerable attention due to its discovery as an important extra- and
intracellular signaling molecule, serving as the mechanism whereby S1P regulates
cell proliferation, survival, differentiation, migration and inflammation. Invariably, with
diverse roles in such cellular activities, disruptions of S1P signaling have been
!
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implicated in the development and progression of cancer, and progress is being made
to therapeutically target the biosynthesis of S1P by targeting the enzymes involved in
the synthesis of S1P: the sphingosine kinases (SPHK1 and SPHK2).54.55
S1P is derived through a process of sphingolipid synthesis and degradation
pathways (Figure 3). At the center of this network is ceramide which is deacylated to
form sphingosine, the precursor to S1P. After phosphorylation of sphingosine by
either SPHK1 or SPHK2, S1P is either exported from the cell or interacts with
intracellular targets to elicit a number of effects. S1P can be exported out of the cell
by members of the ABC transporter family where it acts extracellularly by binding to a
family of five G-protein couple receptors, S1PR1-5. This results in autocrine or
paracrine signalling through the receptors, which are coupled to various G proteins.
Differential expression of the various S1P receptors mediates the cellular response
through the ERK, Rac and Rho, and PI3K/AKT pathways. S1P can be
dephosphorylated

or

degraded

by

S1P

lyase

to

form

hexadecenal

and

phosphoethanolamine.
Current dogma suggests the levels of ceramide, sphingosine and S1P forms a
“lipid rheostat”, whereby the regulation of synthesis and catabolism of these
sphingolipids controls cell fate. Data from cell culture experiments shows that
ceramide and sphingosine are pro-apoptotic and when their levels exceed that of
S1P, the cell is directed towards apoptosis. Ceramide directly activates a number of
targets that mediate its pro-apoptotic functions, including protein phosphatases 1, 2A
and 2C, whereas sphingosine binds and initiates the inactivation of the pro-survival
protein 14-3-3.102-105 Conversely, S1P is anti-apoptotic and results in cellular
proliferation, migration and survival when its production surpasses ceramide and
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sphingosine levels. This is accomplished by modulation of extracellular-signalregulated kinases 1/2 (ERK1/2), Rac and Rho, the phosphoinositides 3-kinase
(PI3K)/AKT pathway and phospholipase C (PLC).105-106 These effects also display
cell- or tissue-specific variability resulting from the differential expression of S1P
receptors and the various G proteins they couple to.107 Thus a delicate balance in the
levels of these lipids has the potential to direct cells toward a pro-survival or proapoptotic outcome.
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Figure 3. Sphingolipid Metabolism. The sphingosine kinases (SPHK1 and SPHK2)
phosphorylate their substrate, sphingosine, producing the bioactive lipid, sphingosine
1-phosphate (S1P). The reverse reaction is catalyzed by S1P phosphatase. S1P can
be irreversibly degraded to produce ethanolamine phosphate and trans-2hexadecenal. The entire sphingolipid metabolic pathway comprises the “sphingolipid
rheostat” whereby the levels of each lipid dictates cell fate. Higher levels of ceramide
and sphingosine, relative to S1P, induces cellular apoptosis. Conversely, when S1P
levels increase above ceramide and sphingosine, the cell is directed to proliferate.
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3.1.2. Sphingosine kinase 2 (SPHK2)
There are two mammalian sphingosine kinases, SPHK1 and SPHK2, which are
located on chromosome 17q25 and chromosome 19q13, respectively.56-57 These
kinases share 80% similarity and 45% overall sequence identity. Both SPHKs contain
five highly conserved regions which contain ATP binding and catalysis regions (Figure
4).

While both catalyze the phosphorylation of sphingosine, SPHK2 contains

additional residues at its N-terminus and central region that are not present in SPHK1,
suggesting that SPHK2 has additional functions.58 Opposing roles of the enzymes
have also been suggested due to the presence of both a nuclear localization
sequence (NLS) and a nuclear export sequence (NES) in SPHK2 that allows shuttling
between the cytoplasm and nucleus.59-60 These sequences are not found in SPHK1.
Additionally, differences in sphingosine kinase expression during embryonic
development suggests SPHK1 and SPHK2 perform separate responsibilities.
Two forms of SPHK2 have been described. The longer isoform (SPHK2-L) has
an additional 36 amino acids at the N-terminus compared to the short isoform (SPHKS).61 Although there is much less sequence conservation in vertebrates in the region
encoding these 36 amino acids compared to the rest of the protein (UCSC Genome
Browser), the SPHK2-L appears to be the predominant form in most human tissues -with the notable exception of the brain and kidney.61 Consistent with this, we have
observed a preponderance of SPHK2-S in human fetal kidney by real-time RT-PCR.
Human and mouse SPHK2-S are highly homologous, with 83% identity and 90%
similarity. Notably, SPHK2-S is the only isoform expressed in the mouse.
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Figure 4. Comparison of SPHK1 and SPHK2. Each kinase contains five conserved
domains. An ATP binding site resides within C2 of each enzyme. SPHK1 (384 amino
acids) and SPHK2 (SPHK2-long: 654 amino acids, SPHK2-short: 618 amino acids)
share 80% similarity and 45% overall sequence identity. Also shown are the SPHK2
long isoform (SPHK2-long) and SPHK2 short isoform (SPHK2-short). These two
SPHK2 isoforms differ by 36 amino acids present at the N-terminus of SPHK2-long.
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SPHK2 possesses an intrinsic catalytic activity which can be enhanced by
growth factors such as EGF.62 This is mediated by ERK1-dependent phosphorylation
at Ser-351 and Thr-578, resulting in a 2-fold increase in catalytic activity.63
Mutagenesis experiments have shown that mutating G212 interferes with ATP binding
and abolishes SPHK2 catalytic activity. Genetic knockout of SPHK1 or SPHK2 in mice
results in no obvious phenotypic abnormalities suggestive of a compensatory
mechanism, while double knockout of both SPHKs is embryonic lethal around E11.5
due to defects in neurogenesis and angiogenesis.64 While no gross phenotypic
anomalies were found in SPHK2 knockout mice, the embryonic and adult kidneys
have not been extensively examined for histological abnormalities (personal
communication – Dr. Richard Proia, National Institutes of Health).
While considerable attention has focused primarily on the cellular activities of
SPHK1, less is known about the function of SPHK2, particularly with respect to
tumorigenesis. Varied roles for SPHK2 in tumorigenesis have been described,
including its ability to induce cell cycle arrest and apoptosis or, in different cell types,
to promote survival and proliferation. A mechanistic role for SPHK2 in the nucleus
was first revealed upon the demonstration that it is co-immunoprecipitated with
histone H3 (but not H4, H2B, or H2A), associates with HDAC1/2 in co-repressor
complexes (including those at the promoters of p21 and c-fos), and results in
increased acetylation at H3-K9, H3-K14 and H2B-K12.65 This function was shown to
be due to SPHK2's phosphorylation of sphingosine and resulting inhibition of
HDAC1/2. Other experimental studies have demonstrated an oncogenic role of
SPHK2 in regulating the proliferation and survival of human acute lymphoblastic
leukemia (ALL) cells. These effects were shown to occur via HDAC2-mediated
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regulation of c-Myc.66 Specific systemic inhibition of SPHK2 (not affecting SPHK1
function or expression) also resulted in a significant reduction in engraftment of
human ALL cells into NOD/SCID mice. Thus, an exciting epigenetic role of SPHK2 in
regulating gene expression is emerging, as is SPHK2's epigenetic role in cancer
development.
3.1.3. SPHK2 in the developing kidney
In the mouse fetal kidney, several components of the sphingosine 1-phosphate
signaling pathway are actively expressed, including the sphingosine kinases, S1P
receptors (S1P1, S1P2, and S1P3), as well as S1P phosphatase and lyase, the
enzymes involved in S1P metabolism. SPHK2 expression is predominately localized
to the metanephric mesenchyme at higher levels than SPHK1 at E11, and gradually
decreases to P4, indicative of a role in nephrogenesis.67 Support for a functional role
also comes from pharmacological ablation of the sphingosine kinases in the
embryonic kidney using small molecular inhibitors. Treatment of embryonic kidney
explant cultures with sphingosine kinase inhibitors, thus blocking the production of
sphingosine 1-phosphate, resulted in reduced branching morphogenesis during
kidney development, underscoring the importance of S1P in development.

3.2.

MATERIALS and METHODS

3.2.1 WTX524 family
Following informed consent from all study participants, blood was drawn from
members of the WTX524 family and peripheral blood DNA isolated for molecular
analysis. The WTX524 family is a Hispanic, multigenerational Wilms tumor family with
nine total cases. The ages of diagnosis ranged from 4-37 months, with an average of
!
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15.3 months (considerably lower than the ~33 month age of diagnosis in familial
Wilms tumor). Unilateral and bilateral tumors were diagnosed in the family, with the
normal kidney tissue of affected children being “unusually rich in nephrogenic rests”
(personal communication with B. Beckwith). Five individuals from the family were
chosen for whole genome sequencing (Figure 5). Sequencing and bioinformatic
analysis was performed as described in chapter 2.
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Figure 5. Pedigree of WTX524 family. Red boxes highlight the six individuals in the family whose whole genomes were
sequenced. This included five affected family members and one married in control.
!

3.2.2. Mutation Analysis of Candidate Genes
Following the identification of candidate genes using next-generation sequencing, a
complete mutation analysis of the genes was performed using Sanger sequencing of
blood DNA from members of the family for segregation analysis. AmpliTaq (Life
Technologies) and primers designed in Oligo (Molecular Biology Insights, Colorado
Springs, CO) were used to amplify genomic DNA in a 25ul reaction volume for 35
cycles. The PCR product was then treated with Exonuclease I and Shrimp Alkaline
Phosphatase. Purified PCR products were then sequenced with target-specific
primers and BigDye v1.1 (Life Technologies). Sequence reactions were purified with
BigDye Xterminator purification kit and run on a Genetic Analyzer 3500 (Life
Technologies). Sequence analysis was next performed with MutationSurveyor (Soft
Genetics). If the candidate variant co-segregated with the affected/obligate carrier
status, the mutation analysis was extended to one member of 48 Wilms tumor families
to assess the frequency of candidate gene mutations in familial Wilms tumor samples.
Additionally, qPCR was used to detect exonic deletions and duplications of the
candidate gene. qPCR primers targeting exons (including exon/intron boundaries)
were designed using Primer Express. Primer sets for mutation analysis of each gene
by Sanger sequencing and qPCR are listed in Tables 2-3.
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SANGER
PRIMERS
FORWARD Primer
SPHK2 exon 2
SPHK2 exon 3
SPHK2 exons 46
SPHK2 exon 7a
SPHK2 exon 7b
TRPM4 exons 12
TRPM4 exon 3
TRPM4 exons 46
TRPM4 exons 79
TRPM4 exon 10
TRPM4 exons
11-12
TRPM4 exons
13-14
TRPM4 exons
15-16
TRPM4 exon 17
TRPM4 exons
18-19
TRPM4 exon 20
TRPM4 exons
21-25
GADD34 exon 2
GADD34 exon 3

AGCCTTCACTCCTATTAT
CACCTGTCTGAGCCTGTCTG

REVERSE Primer
GATTTTGTCTTTCCACAGTA
T
CACATCCGGTCCTCTTGTCT

GGGCTGGAAGTAACCTAA
ACCCACAGTCAGTCAAGTAA
GACGGGTGAGTGTAG

GCGCTCGGGATACAG
GACGGGTGAGTGTAG
CTGCCACCACAACTCTA

TGTCCCTCTGTCCCCTTAT
CACAGACCCAAACGCTCCTA
CCCTCAGAGAGAAGATAGGT CTCTACAGGAGCATGAACAC
CCATGTGTCCACAGTTCC

TCTCGACCAGACCAAACTAC

ACTCCTGGGAAATGCG
ATGACCTTATGCCTATGATA

AAAATATTAAGAGGGGTAAA
AGAGAGGGAGGACAGCAC

GCCCATCTCTTGTCCTTAAC

TCGGGGAATTGTATG

CCATCTCCAAACATTACTTCA GAGAGTGGCTGGTCAAG
TTGCCTTTCACCACCGTTTC
AGACTGAGTTTCGGGTCA

TCTCGCCATGTGATACACTG
CTGAGTGGCGGACA

CCGCGTCTGTCCATAC
CGCCTGGCTAACAGT

AAACTGCTGGCGAGTGTA
ATCAGAGTTCAGGGACTAAA

TACAGGCGTGACCAA

AAGGGAGGAAACGGACTC

CACACCGGGAGTGTTGT
ATAGAGAATCCCGTGACAGT

AAATAGAATCTGGGCTCTCA
G
TACAGACGCTGCTCGCTACA

Table 2. Primer sets for mutation analysis of three candidate genes by Sanger
sequencing.
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qPCR PRIMERS
SPHK2 exon 1
SPHK2 exon 2
SPHK2 exon 3-4
SPHK2 exon 5-6
SPHK2 exon 7
TRPM4 exons 1-2
TRPM4 exon 3
TRPM4 exons 4-6
TRPM4 exons 7-9
TRPM4 exon 10
TRPM4 exons 11-12
TRPM4 exons 13-14
TRPM4 exons 15-16
TRPM4 exon 17
TRPM4 exons 18-19
TRPM4 exon 20
TRPM4 exons 21-25
GADD34 exon 1
GADD34 exon 2
GADD34 exon 3

FORWARD Primer
CTCTACCACGATCCGGA
CTTCT
CCAGGGTCCCGTTGATG
TAA
GTCTGAGCCTGTCTGTC
TCTGATG
CTGAGTCCTAAGGGAGC
AAAGTG
TCCGTCCCCAATCTAAA
AAGC
CCGGATCTGTGGAGTCA
ACTATG
CGGCCCCCGTGAAGTC
AGACCAGGGCGTCTCCT
CAT
CCAGCCACGAGGAGACA
TG
GTTCCAAGCCACAGCCA
AA
GATGCAGGAGCGCCAA
GT
CCTCACCTCACTGCTGC
GATA
GACAGGCCCTTCCCCAT
TAA
AGTGGGCAGGAAGGAT
GAGA
CCGTGAAAACCATGAAG
TCGAT
AGGAGGGTGTGCCCAG
AAG
GCCCCGCTCTCACTTCT
G
TGGGATGGGAACCGATA
AGA
CCCAAGACTCCAACTCA
ATTAAAAA
CGCTGCTCGCTACAAAT
CAA

REVERSE Primer
TTGGACGTTGCGCTTGTTC
ATGAGGATCTTGGCTTTTAG
ATGGT
CTGTGGGAAGGGAGGAGA
GAA
CTGTCGTTCTGAAGTGGGA
TACC
GCTGGAAGTGCTGGAGTCT
GA
TGCCCTCTCACCCCACTTC
CCGCAGTGGCCATGGA
CGGAATAGAGACACCCTCA
TCAA
GGTGAATATCCTGCCTTTTC
TGA
TTGTCCCCTCTCCCTCTAAT
CC
CCCTGGAGCGACCTGCTT
TCACACCCTCACCCTACTC
CTT
TTCTCTTCCCCTCATTTCTT
GCT
CTCGCCGACAGCTGGAA
ACACTTGACCCTTGTGGCA
TCT
TCACCCCATCTCTGAATGTC
TCT
ATCGGTGCATAAGGAGAAC
TTTCT
TCGAAACCCCGCCTCTCT
GCTCAAGCGCCCAGAAAC
GGGAGGCGTGGCTGAGA

Table 3. Primer sets for the detection of exonic deletions in candidate genes by
qPCR.
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3.2.3. Gene Expression by qPCR
SYBR Green (Applied Biosystems) was used for analysis of SPHK2 gene
expression. RNA was isolated from lymphoblastoid cell lines using Trizol, quantified
and used for cDNA synthesis using MultiScribe Reverse Transcriptase and PCR
Master Mix according to the protocol (Invitrogen). Forward and reverse primers for
detecting expression levels of specific genes were designed using Primer Express
(Applied Biosystems). Quantification of expression was performed using SYBR green
and the ABI 7900 HT sequence detection system (Applied Biosystems). Gene specific
Ct values were compared across samples relative to GAPDH levels and calculated as
fold differences to a control reference value whose expression was designated as 1.
qPCR primer sequences are listed in Table 4.

Forward primer
p21

CGATGGAACTTCGACTTTGTCA

c-fos

CACTCCAAGCGGAGACAGAC

c-myc

GGCTCCTGGCAAAAGGTCA

Reverse primer
GCACAAGGGTACAAGACA
GTG
AGGTCATCAGGGATCTTG
CAG
CTGCGTAGTTGTGCTGAT
GT

SPHK2-L

ATGAATGGACACCTTGAAGCAG

CATGGCCTTAGCCCTGAC
CAG

CTGTCTGCTCCGAGGACTGC

CAAAGGGATTGACCAATA
GAAGC

SPHK2-Total

Table 4. qPCR primers for expression profiling of SPHK2 isoforms and target genes.
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3.2.4. Generation of SPHK2 constructs
Human SPHK2-S and SPHK2-L cDNA was amplified from a SPHK2 image
clone (Origene, SC113181) using the primers listed in Table 5. A PCR product of the
correct size was gel purified and enzymatically treated with XbaI and XhoI restriction
enzymes for 1 hr at 37*C. This digested PCR product was then treated with Mung
Bean nuclease to produce blunt ends, as well as shrimp alkaline phosphatease at
37*C for 30 min. The product was then ligated into a pcDNA3.1 V5/His expression
vector (Life Technologies). The ligation reaction was performed at 16*C overnight,
followed by transformation into competent E.coli cells overnight. Colonies were
screened by cutting with EcoRI at 37*C for 30min, followed by gel electrophoresis.
Those that appeared to have integrated the plasmid + insert of the correct size were
grown overnight at 37*C and screened by PCR for the correct insertion of the plasmid.
QuikChange site directed mutagenesis was performed using manufacturer’s protocol
to introduce the R100W and R136W mutations. Sanger sequencing confirmed the
introduction of the mutation. Plasmids containing the mutation were grown overnight
at 37*C and used for Midi-prep of DNA. The same procedure was repeated to
generate mouse SPHK2 constructs using mSPHK2 cDNA and mouse-specific SPHK2
primers. Site directed mutagenesis was used in the generation of mutant mouse
SPHK2 (R100W – the equivalent of the human R136W mutation) constructs.

3.2.5. Transient and stable-transfected cell lines
To generate transient and stable-transfected cells for functional experiments,
MCF7 (a human breast cancer cell line) and M15 (a mouse renal mesenchymal cell
line) cells were seeded in 6-well plates and incubated at 37*C overnight. Transfection
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using Lipofectamine 3000 (Life Technologies) was performed at a ration of 3:1 (lipid
complex/DNA) and incubated overnight. The following day, the transfection reagent
was removed and cells were used for 1) transient expression experiments, or 2)
seeded in 10cm culture plates along with 1ug/ml G418 for 2 weeks to select for stable
transfectants. Following selection with G418, cells stably expressing the plasmid were
seeded sparsely into 10cm plates for isolation of single colonies. Single colonies were
trypsinized and seeded into 24-well culture plates, along with media supplemented to
G418. Once the colonies were confluent, they were trypsinized and seeded into 12well plates. The process was repeated using larger culture volumes until enough cells
were obtained for experiments.
M15 cell lines with the R101W mutation (analogous to the human SPHK2R136W)
introduced into the endogenous locus of SPHK2 were generated using CRISPR/Cas9
genome engineering. These cell lines were a gift from E. Cristy Ruteshouser and
used for gene expression studies described below.

3.2.6. Western Blot Analysis
SPHK2-stable transfected MCF7 cells were washed with ice-cold PBS and
scrapped in SPHK2 lysis buffer containing 50mM HEPES, 150mM NaCl, 1mM EDTA,
1% Triton X-100, 2mM sodium orthovanadate, 4mM sodium pyrophosphate, 100mM
NaF, and 1:500 protease inhibitor mixture. Lysates were sonicated and centrifuged at
14,000 x g for 15 min and quantified with the BioRad protein assay and
spectrophotometer. Equal amounts of protein lysates (20ug) were used for
subsequent analysis. Protein lysates were denatured for 10 min at 99 °C with βmercaptoethanol before loading into BIORAD Mini-PROTEAN TGX Precast Gels with
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Laemmli running buffer at 90 volts for 2 hrs. Following gel electrophoresis, proteins
were transferred to nitrocellulose membranes using BIORAD Mini Trans-Blot cell
assembly run at 22V at 4 °C overnight. Membranes with bound proteins were blocked
for 1 hr in 5% milk in TBST (1X Tris buffered saline/0.1% Tween-20) followed by
incubation with primary antibody in 5% milk in TBST for 1 hr at room temperature.
Membranes were then washed 3 times with TBST, followed by a 1 hr incubation with
secondary antibody (donkey anti-rabbit IgG, GE Healthcare, NA934V) diluted 1:5000
in 5% milk in TBST at room temperature. Following 3 washes in TBST, membranes
were developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific) according to the protocol.
3.2.7. Immunofluorescence
For immunofluorescence studies of cultured cells, cells were plated in 8-well chamber
slides (LabTek) and allowed to adhere overnight before fixation with 4%
paraformaldehyde for 15 min. The slides were then incubated with 0.5% Bovine
Serum Albumin in in PBS for 1 hr, followed by washing three times with PBS. Primary
antibodies (anti-V5, 1:1000) were added to the chamber slides followed by a 1 hour
incubation at room temperature. Chamber slides were then washed three times in
PBS and incubated with secondary antibodies Alexa Fluor-488 (Invitrogen) for 1 hr in
the dark. Subsequently, the slides were washed three times in PBS and stained using
ProLong Gold anti fade reagent with DAPI (Invitrogen) and allowed to air-dry
overnight at 4 degrees in the dark.
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3.2.8. Proliferation Assay
To measure proliferation, MCF7 stably-transfected cells and M15R101W cells
were plated on 8-well chamber slides (LabTek) and incubated overnight. Detection of
a modified thymidine analogue (EdU) incorporated into newly synthesized DNA was
performed using the Click-iT Plus EdU Alexa Fluor 488 Imaging Kit (C10637, Life
Technologies) following manufacturer’s protocol. Images were captured using an
Olympus BX60 fluorescence microscope and quantified using MetaMorph Microscopy
Automation and Image Analysis Software.

3.2.9. Apoptosis Assay
Apoptosis of M15 cells was performed using the DeadEnd TUNEL assay
(Promega) according to manufacturer’s instructions with the following modifications:
1) Cells were plated in 8-well chamber slides (LabTek) instead of cover slips. Images
were captured using an Olympus BX60 fluorescence microscope.

3.3.

RESULTS

3.3.1. Whole genome sequencing identifies candidate familial Wilms tumor
predisposition gene: SPHK2
To identify the 19q FWT gene, we sequenced the whole genomes of five affected
individuals and one married-in control within a large multigenerational WT family. The
coverage was approximately 30X across all members (Figure 6). We first looked for
shared variants between the 5 affected individuals, and filtered out all variants that
were in common with the married-in control. This resulted in 206,860 variants
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remaining across the entire genome. After excluding variants previously found in
dbSNP or those present at a frequency of >1% in 1000 Genomes Project data, we
were left with 20,517. A total of 18 exonic variants were identified from this analysis,
of which 10 variants were nonsynonymous and 8 were synonymous (Table 6). Of
these, we observed 1 in the 19q linked region (Table 7). The other variants we
identified were eliminated from further consideration because they were 1) located
outside of the 19q linked region and 2) not plausible candidates for having an obvious
role in kidney development. In addition to SPHK2, two candidate variants were
identified within the linked region that were novel at the time of discovery. However
they have since been reported with minor allele frequencies greater than 1%. A
comprehensive mutation analysis of the two genes, TRPM4 and PPP1R15A,
excluded these genes as candidate familial Wilms tumor predisposition genes based
on 1) identification of potentially deleterious variants coming from the unaffected
married-in parent and absence of the variant in the affected parent, and 2) their
increased population frequency with the continued development of variant databases.
Our analysis left us with one candidate, sphingosine kinase 2 (SPHK2).
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Figure 6. Coverage across the whole genome for six members of the WTX524 family.
The coverage was approximately 30X for all members, which is sufficient to call
germline variants at high confidence.
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Table 6. Shared single nucleotide variants (SNVs) and insertions/deletions (indels)
across the entire genome from five WTX524 family members with Wilms tumor.
Further filtering using data from the married-in control resulted in the variant numbers
listed on this table. Included in the analysis are those shared across the entire
genome, as well as novel and rare (minor allele frequency < 1%) variants occurring
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Table 7. Candidate familial Wilms tumor predisposition genes following the
application of all filtering criteria. Variants listed here are those that are novel/rare,
shared by five affected Wilms tumor family members, and not found in the spousal
control. Conservation scores are represented using PhyloP. Expression in fetal kidney
(FK) was determined using gudmap.org.
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The SPHK2 variant (chr19:49129514, GRCh37/hg19, c.772C>T, p.R136W)
was present in roughly 50% of the sequence reads indicative of a heterozygous
germline variant and occurs at an evolutionarily conserved amino acid residue
indicated by a PhyloP score of 0.999 (Figure 7-8). Substitution of an arginine for a
tryptophan at this position is predicted to be deleterious (SIFT-0, PolyPhen-0.999).
This variant was not identified in >60,000 individuals whose exome data were
included in the Exome Variant Server (http://wvs.gs.washington.edu/EVS/). The
R136W mutation does not fall within a currently defined domain of SPHK2, although it
should be noted that SPHK2 is poorly characterized at this point. Interestingly, the
R136W mutation occurs within six amino acid residues from the nuclear localization
sequence.

3.3.2. SPHK2R136W co-segregates within the family
We confirmed the co-segregation of the germline, heterozygous mutation in all
affected and obligate carrier members of the family using Sanger sequencing (Figure
9). In total, 17 mutation carriers were identified, 8 of which developed Wilms tumor
(47%). The variant was not identified in 11 other family members tested, 7 of which
were married-in, spousal controls. Sequencing this same exon in a tumor sample from
the family showed heterozygosity for the mutation, indicating the wildtype allele was
not lost somatically in the tumor. Sanger sequencing of the entire SPHK2 coding
region was then performed in the tumor sample for the assessment of possible
compound heterozygosity. No somatic SPHK2 mutations were identified in the tumor.
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Figure 7. Visualization of the region surrounding the SPHK2 variant (R136W) using
the Integrative Genomics Viewer (IGV). The variant allele (T) is present in roughly
50% of the sequence reads, indicative of a heterozygous variant. This figure is
representative of the sequence reads from five affected individuals in the WTX524
family.

Figure 8. Amino acid sequence conservation of the R136W variant and surrounding
residues. Analysis by PhyloP was also used for conservation.
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Figure 9. Cosegregation of the R136W variant by Sanger sequencing. Primers
targeting exon 3 of SPHK2 were used to assess cosegregation within the family.
These sequence traces represent the unaffected and affected/obligate carriers whose
DNA was assessed in the WTX524 family.
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3.3.3. Comprehensive SPHK2 Mutation Analysis in Familial Wilms tumor
A complete mutation analysis of all seven exons of SPHK2 was performed in
one member from 47 additional Wilms tumor families. This mutation analysis included
Sanger sequencing, as well as qPCR for the detection of exonic deletions (Table 8).
No germline deletions were detected by qPCR. However, five variants, either novel or
with a minor allele frequency of less than 1%, were identified in six Wilms tumor
families by Sanger sequencing. Two of these alterations, P83P (rs151257086) and
L249L (rs116785119), were synonymous mutations not predicted to alter splicing
(ALAMUT). A novel, heterozygous 5’ UTR variant (49123707A>C) was found in one
WT family, however its affect on SPHK2 expression is unknown. Additionally, a rare
missense mutation (p.G601A, rs61751862) was identified in two Wilms tumor families.
This rare variant has a population frequency of 0.000014 and has been reported in
1/69,600 individuals (Exome Aggregation Consortium, exac.broadinstitute.org). Like
the R136W mutation, the G601A also does not occur within a currently defined
domain of SPHK2. All germline missense mutations identified in familial Wilms tumor
samples were predicted to be damaging by at least one of the prediction algorithms
and segregated with the affected/obligate carrier status in each family.
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Table 8. Comprehensive SPHK2 mutation analysis, including Sanger sequencing and
qPCR, of all seven SPHK2 exons in one member of 47 Wilms tumor families identified
novel/rare nonsynonymous and synonymous germline mutations.
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3.3.4. SPHK2 Mutation Analysis in Sporadic Wilms tumor
Many cancer genes have been identified whose germline mutation predisposes
to cancer and whose somatic mutation also plays key roles in the etiology of nonfamilial cancers, which account for the majority of cancers in the general population.
To assess the frequency of SPHK2 variants in non-familial tumors, we extended our
screening to 175 sporadic Wilms tumors. Sanger sequencing of 175 sporadic Wilms
tumor samples was performed using primers targeting each exon of SPHK2. Eleven
variants (5 missense, 6 synonymous) were identified in this analysis (Table 9). The
five nonsynonymous variants were all previously reported in variant databases at a
frequency of less than 1%, and all were predicted to be pathogenic by at least one
prediction algorithm. Sanger sequencing of the corresponding blood sample from
each individual was performed to determine if the variants occurred in the germline or
were somatically acquired. The only somatic variant was a novel synonymous
mutation (F135F) identified in one tumor. The potential impact of synonymous
variants on splicing was assessed using ALAMUT. One variant, P380P, was predicted
to activate a cryptic splice site in exon 7 of SPHK2. Of the five tumors in which a
SPHK2 variant was identified, three contained an additional alteration, including
somatic CTNNB1 mutation (Ser22Cys), germline WT1 mutation, and loss of the
wildtype SPHK2 allele.
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Table 9. Comprehensive SPHK2 mutation analysis of all seven SPHK2 exons in 176
sporadic Wilms tumor samples identified novel/rare nonsynonymous and synonymous
SPHK2 mutations.
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3.3.5. Functional impact of SPHK2 mutation
3.3.5.1.

SPHK2-short is predominant form in fetal kidney

Before investigating the functional significance of the SPHK2 R136W variant
identified in the WTX524 family, we confirmed expression of SPHK2 in human fetal
kidney using human fetal kidney RNA purchased Clontech Laboratories. Consistent
with results from mouse expression profiling, we observed expression of SPHK2 in
the embryonic kidney. It was previously reported that SPHK2-L was the predominant
isoform expressed in most human adult tissues and cell lines screened to date except
the kidney and brain, where the expression of both short and long isoforms appeared
equal. Using isoform-specific qPCR primers, we observed 5-fold greater expression (p
= 0.001) of SPHK-S in the human fetal kidney, suggesting the short isoform has a
more significant role in kidney development (Figure 10).

3.3.5.2. SPHK2R136W impairs nuclear localization and alters gene expression in
MCF7 cells
The SPHK2 variant we identified in the family has not been reported to date.
As a result, there is no data describing the functional impact of this nonsynonymous
mutation on protein function. Moreover, SPHK2 has not been as extensively studied
as SPHK1, and literature describing protein domains and their respective functions
are lacking. Although the mutation we identified within the family does not fall within a
currently-defined domain of SPHK2, it is in close proximity (within 6 amino acid
residues) to a previously characterized nuclear localization signal.
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Figure 10. Expression of SPHK2-Total and SPHK2-Long in human fetal kidney.
Primers were designed to target a region common to both isoforms (termed SPHK2total) and a region specific to the long isoform (SPHK2-Long). The difference between
the two represents expression of the SPHK2-short isoform.
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This ability of SPHK2 to localize to the nucleus is crucial for its role in epigenetic
regulation of gene expression.65 In order to determine if this alteration is functionally
significant as suggested by a number of prediction algorithms, we generated SPHK2
constructs (SPHK2-Long and SPHK2-short) containing the same mutation we
identified in the family to assess the impact of the mutation on subcellular localization.
Using site-directed mutagenesis, SPHK2R100W was introduced into the SPHK2-short
isoform, and the analogous SPHK2R136W was introduced into the SPHK2-long isoform.
These mutant constructs, as well as the wildtype controls, were transiently transfected
into MCF7 cells. We chose this cell line because 1) it expresses SPHK2 at a low level
(so endogenous wildtype protein is less likely to obscure the effect of the exogenous
mutant protein) and 2) it was the cell line used for the initial characterization of
SPHK2’s role in the nucleus to interact with HDAC1/2 and histones and to regulate
gene expression in an HDAC1/2- dependent manner. This allowed us to directly relate
our data on SPHK2R136W to published findings. Expression of the constructs at the
mRNA and protein levels were confirmed (Figure 11). Using immunofluorescence, we
observed a significant reduction (p = 0.029) of mutant SPHK2 in the nucleus
compared to the cytoplasm (Figure 12a). As expected, the expression of target genes
(p21 and c-myc) was significantly increased when wildtype SPHK2 was expressed in
MCF7 cells, an observation consistent with previous reports (Figure 12b). In contrast,
expression of mutant SPHK2 resulted in a significant reduction of p21 and c-myc,
consistent with altered subcellular localization of mutant SPHK2.
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Figure 11. Expression of wildtype and mutant SPHK2 was confirmed at the mRNA
and protein levels using qPCR and western blotting, respectively, in MCF7 cells
transfected with human SPHK2 overexpression constructs.
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Figure 12a. Immunofluorescence using DAPI (nuclei) and anti-V5 (SPHK2)
antibodies to visualize wildtype and mutant SPHK2 localization after transient
transfection in MCF7 cells. Intensity of the anti-V5 signal from the nucleus and
cytoplasm was quantified with ImageJ, and presented as the nuclear/cytoplasm ratio.
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Figure 12b. Expression of SPHK2 target genes in MCF7 cells were assessed by
qPCR after transfection with wildtype and mutant SPHK2 expression constructs.
(p values * = <0.02; # = 0.03)
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3.3.5.3. SPHK2R101W impairs nuclear localization in M15 cells
Our previous data suggests that the SPHK2 R136W mutation identified within
the WTX524 family alters nuclear localization and subsequent gene expression in
MCF7 cells. In order to investigate the significance of the variant in a system more
relevant to that of kidney development, wildtype and mutant mouse SPHK2
expression constructs were generated and used for transfection experiments in a M15
cell line, a renal mesenchymal cell line similar to the cells in the embryonic kidney that
are thought to give rise to Wilms tumors. Wildtype and SPHK2R100W (analogous to the
human SPHK2R136W) constructs were transiently transfected into M15 cells and
subcellular localization of SPHK2 protein examined using immunofluorescence. We
observed a significant reduction in SPHK2R100W nuclear localization compared to
wildtype protein (Figure 13). These results were consistent with the analogous
experiment in MCF7 cells, providing confirmation of our results in two experimental
systems.
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Figure 13. Immunofluorescence assay shows reduced nuclear accumulation of
SPHK2R101W compared to wildtype SPHK2. Intensity of the anti-V5 signal from the
nucleus and cytoplasm was quantified with ImageJ and presented as the
nuclear/cytoplasm ratio.
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3.3.5.4. SPHK2R101W alters expression of kidney developmental genes.
Data from our previous experiments suggest that SPHK2R136W alters gene
expression following mislocalization of mutant SPHK2 to the nucleus. These studies
used overexpression of SPHK2 in MCF7 cells, which express very low levels of
SPHK2. In order to assess the effect of this mutation in a fetal kidney experimental
system with no manipulation of gene expression level, we examined expression of
genes expressed during kidney development using cells in which the SPHK2R101W
mutation was introduced into the endogenous locus of SPHK2 via the Clustered
Regularly Interspaces Short Palindromic Repeat (CRISPR/Cas9) system. M15 cells
carrying the homozygous SPHK2R101W alteration were generated previously in our lab
(E.C. Ruteshouser). Gene expression profiling of selected kidney developmental
genes (CDN11, CSRP1, GDNF, LHX1, MLL5, NR2F2, OSR1, SPRY1, EYA1,
FOXD1, WNT4, WT1) was assessed in M15wt and M15R101W cells using qPCR (Figure
14). Of these genes, EYA1 was significantly upregulated in mutant cells compared to
wildtype M15 cells. One disadvantage of CRISPR/Cas9 mutagenesis is the possibility
of off-target activity due to sequence similarity of the guide RNA with other regions of
the genome. Although these target sites (predicted using the CRISPR Design Tool)
were screened by PCR amplification and Sanger sequencing and revealed no offtarget activity, our analysis included three M15R101W clones generated simultaneously
with CRISPR/Cas9 to account for potential off target effects not predicted by the
prediction software.
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Figure 14. Gene expression profiling of 12 genes expressed during kidney
development using wildtype M15 cells, as well as three M15 cell lines containing the
R101W mutation generated by CRISPR/Cas9. EYA1 was consistently upregulated in
each of the three mutant cell lines, whereas other genes do not appear to be altered
in SPHK2 mutant cells. The expression of EYA1 in each mutant clone was
significantly upregulated compared to wildtype (p value = <0.01).
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3.3.5.5. SPHK2R100W does not affect proliferation or apoptosis
There are several reports of phenotypic effects observed upon SPHK2
overexpression, down-regulation, or inhibition in cell lines. Wildtype SPHK2 has been
shown to promote both proliferation and apoptosis, depending on the cell type used.
These contradictory results appear to be due, at least in part, to the different
subcellular localization of SPHK2 and its product, S1P, between cell types. We
investigated the effect of mutant SPHK2 on proliferation in M15 cells containing the
SPHK2 mutation knocked in to the endogenous locus and noted no significant
difference between wildtype and mutant SPHK2 cells, suggesting the genes regulated
by SPHK2 are not involved in cell proliferation of M15 cells (Figure 15). Additionally,
apoptosis was also examined in wildtype and mutant M15 cells, and no significant
differences were observed (Figure 16).
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Figure 15. Cell proliferation assay using wildtype M15 cells and three SPHK2R101W
mutant clones. Proliferation was measured by incorporation of EdU, a thymidine
analogue, into proliferating cells.
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Figure 16. Apoptosis assay using wildtype M15 cells and three SPHK2R101W mutant
cell lines. No differences in apoptosis between wildtype and mutant cells were
detected. Incorporation of fluorescein-12-dUTP at 3’-OH ends of fragmented DNA
was visualized by fluorescence microscopy.
!
!

!

64!

3.4.

DISCUSSION!
Next-generation sequencing has recently facilitated the discovery of genes

involved in sporadic Wilms tumor cases, resulting in significant progress in
understanding how aberrant development leads to cancer. However, the gene
mutations predisposing to familial Wilms tumor are generally unknown. Familial Wilms
tumor is genetically heterogeneous, and in order to understand the mechanisms of
tumor formation, the mutated gene(s) involved must first be identified. Fortuitously,
next-generation sequencing allows for cost-efficient, high throughput surveying of the
entire genetic landscape in an unbiased manner to identify genes causing disease.
Following a whole genome sequence analysis of members of a large
multigenerational 19q-linked Wilms tumor family, we identified variants shared by
affected/obligate carriers in the family and analyzed their potential to be candidate
Wilms tumor predisposition genes. Using this family based sequencing approach,
which included 5 affected family members and 1 spousal control, we were able to
significantly reduce the number of candidate variants for further investigation. Of the
10 exonic variants identified from this analysis, one was located within the 19q linked
region previously characterized by our lab. As a result, we have successfully identified
mutations in SPHK2, which encodes sphingosine kinase 2, as a candidate familial
Wilms tumor predisposition gene.
The SPHK2 variant (R136W) identified in our study is novel, co-segregates
with the affected/obligate carrier status in the family, occurs at an evolutionarily
conserved amino acid residue, and is predicted to be deleterious by several prediction
algorithms. Identification of SPHK2 mutations in other Wilms tumor families, as well
as sporadic Wilms tumor cases, further implicates SPHK2 as a gene contributing to
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Wilms tumor development. SPHK2 variants are noted in a variety of cancers in the
COSMIC database, and these are almost exclusively missense mutations. These data
argue that the SPHK2 mutations are functionally significant due to encoding a protein
with an altered function. Our data suggests that the SPHK2R136W is indeed deleterious
to protein function by reducing nuclear localization in MCF7 and M15 cell lines.
Because mutant SPHK2 can not properly localize to the nucleus, target gene
expression is altered.
SPHK2 is expressed in the embryonic kidney, with its highest levels occurring
in the metanephric mesenchyme during early nephrogenesis. Therefore, SPHK2 is
highly expressed in the cells thought to give rise to Wilms tumors. Previous reports
show significantly increased SPHK2 mRNA in WiT49 cell and Wilms tumor samples
compared to matched normal tissues, indicating that SPHK2 may have a functional
role in Wilms tumor. Not only is SPHK2 actively expressed in the fetal kidney, but
components of its nuclear co-repressor complex such as HDAC1/2, are differentially
expressed during nephrogenesis as well. Interestingly, HDAC1/2 has only recently
been recognized as critical for kidney development. Inhibition of histone deacetylase 1
and 2 in the metanephric kidney results in the specific downregulation of genes
driving differentiation (WT1, EYA1, SALL1). SPHK2 has an important role in
chromatin regulation,65 which is becoming increasingly recognized as playing a major
role in tumorigenesis. SPHK2 itself has recently been demonstrated to have a
significant role in leukemogenesis through its effect on HDAC2-dependent regulation
of c-Myc expression. Our identification of SPHK2 mutations in both familial and
sporadic Wilms tumors (Figure 17), and the observation that the SPHK2R136W results
in modification of gene expression, suggests that, like mutations in WT1 (encoding a
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Figure 17. Summary of SPHK2 mutations identified in both familial and sporadic Wilms tumor
cases from our study.

transcription factor), mutant SPHK2 alters gene expression in the developing kidney
which results in the presence of cells predisposed to malignant transformation. In the
case of SPHK2, the mechanism for this altered expression would be via altered
chromatin regulation. Interestingly, as more pediatric sequencing studies are being
completed, the number of mutations in genes involved in chromatin regulation and
remodeling have outweighed the relative lack of mutations in classic oncogenes and
tumor suppressors in childhood cancers, suggesting epigenetic events contribute
more frequently to the incidence of pediatric cancer cases.
Analysis of tumors from families linked to chr17q, a region containing another
familial Wilms tumor predisposition gene (known as FWT1), showed no loss of
heterozygosity of polymorphic microsatellite markers within the 17q-linked region.68
This was also observed with the 19q-linked tumors as well, indicating that these
genes might not function as classical tumor suppressors. In our analysis, the SPHK2
R136W mutation was heterozygous in the germline, as well as in two tumor samples
from affected members of the family. Furthermore, mutation analysis of all seven
exons of SPHK2 showed no additional somatic mutation in either tumor. Likewise, all
SPHK2 variants we identified in familial and sporadic cases were heterozygous as
well, with the exception of one sporadic case (germline P654H, tumor specific LOH).
Taken together, this suggests that mutation of the familial Wilms tumor predisposition
genes may be necessary for the initiation of Wilms tumors, but are not sufficient to
result in disease. Mutations elsewhere in the gene (regulatory or intronic regions), in
additional genes, or the action of modifier genes might be necessary for tumor
development from precursor lesions.
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As mentioned previously, the kidneys of members of the Wilms tumor family carrying
the germline SPHK2 mutation were "unusually rich" in nephrogenic rests, a precursor
to Wilms tumor. In our lab’s existing mouse model of Wilms tumor, in which mosaic
somatic ablation of Wt1 in the context of upregulation of the fetal mitogen Igf2, we
observe both tumors and foci of undifferentiated mesenchyme, like nephrogenic rests.
Mice with mosaic somatic ablation of Wt1 in the absence of Igf2 upregulation also
display such foci. Based on these data and the role of SPHK2 in epigenetic regulation
of gene expression, we speculate that the missense mutation has an effect on normal
metanephric

mesenchyme

differentiation

such

that

foci

of

undifferentiated

mesenchyme (nephrogenic rests) develop. This is consistent with our data
demonstrating a significant increase in expression of Eya1 in a M15 cell line in which
the R100W mutation was knocked into the endogenous Sphk2 locus. Eya1, along
with Wt1 and Pax2, is a transcription factor expressed early in kidney development in
the metanephric mesenchyme and is involved in the maintenance of nephron
progenitors.101 Deletion of Eya1 in this population of cells results in premature
differentiation and depletion of nephron progenitor cells by acting upstream of Six2.
We can speculate that the increased expression of EYA1 contributes to the formation
of nephrogenic rests by maintaining the self-renewal of nephron progenitor cells, as
deletion of Eya1 results in the loss of Six2 expression and premature differentiation of
the progenitors.
In our model, SPHK2 mutation carriers are at a higher risk of Wilms tumor
development due to the presence of nephrogenic rests. Neoplastic transformation of
these precursors then proceeds following an additional alteration acquired within the
nephrogenic rest, such as upregulation of Igf2, an alteration commonly observed in
!
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Wilms tumors, but which, alone, is not sufficient for tumor development. Additional
experiments using mouse models will further clarify this hypothesis. However, it is
clear that SPHK2 and sphingolipid metabolism is an emerging pathway in cancer
development. Our identification of SPHK2 as a candidate familial Wilms tumor
predisposition gene and our analysis of the functional significance of its mutation in
mouse mesenchymal cells suggests a role in regulation of kidney developmental
genes.
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CHAPTER 4: Identification of novel DICER1 mutations in Wilms
tumor families

4.1.

INTRODUCTION
Since the identification of DICER1 mutations in rare Wilms tumor cases in

2011, studies using next-generation sequencing have found that the microRNA
processing pathway is sometimes mutated in Wilms tumors. As a result, these studies
have provided a glimpse into the mechanism of Wilms tumor development through
altered production of small RNAs regulating gene expression. The enzymes
responsible for processing these microRNAs are crucial for mature microRNA
expression and have thus emerged as key players of nephrogenesis and Wilms
tumorigenesis.

4.1.1. MicroRNAs
MicroRNAs (miRNAs) are small, ~22 nucleotide noncoding RNAs that regulate
gene expression post-transcriptionally.69 With important roles in cellular processes
such as differentiation, development and the cell cycle, dysregulation of miRNA
biogenesis can serve as the key driving mechanisms of tumor formation.70-74 Recent
studies have identified miRNAs and the enzymes involved in their production as vital
factors for the proper development of the kidney.75 More than 170 miRNA families
present in the embryonic kidney have been identified by deep sequencing. These
miRNAs, including members of the miR-200 family, regulate the expression of genes
critical for the formation of the mature kidney, as well as support differentiation and
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survival of nephron progenitors, podocytes, juxtaglomerular cells and ureteric
epithelium.76-79
The biogenesis of miRNAs proceeds in a stepwise progression that is
subjected to multiple levels of regulation (Figure 18). This process begins when long,
primary transcripts (pri-miRNAs) are transcribed in the nucleus by RNA Polymerase II.
Interaction of pri-miRNAs with the nuclear microprocessor complex consisting of
DiGeorge syndrome critical region 8 (DGCR8) and DROSHA, the nuclear counterpart
of DICER1, results in the cleavage of the RNA to a 60-70 nucleotide pre-miRNA.80-83
These hairpin-folded pre-miRNAs are exported to the cytoplasm by exportin 5
(XPO5).84-86 In the cytoplasm, pre-miRNAs interact with DICER1, where they are
cleaved into ~20 nucleotide double stranded RNAs.87 These ~20-nucleotide mature
miRNAs are loaded into the RNA-induced silencing complex (RISC), where they bind
to target mRNAs. Each miRNA can regulate the expression of 50-100 mRNAs by
binding through sequence complementarity of its 8-nucleotide seed sequence to
target sites occurring in the 3’-UTR of genes and silencing by miRNA-mediated
degradation or disruption of the ribosomal complex. Consequently, proper cleavage of
the miRNAs by DICER and DROSHA is important in maintaining the correct seed
sequence for recognition of target mRNAs.
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Figure 18. Micro RNA biogenesis pathway. miRNAs are transcribed in the nucleus by
RNA Polymerase II as pri-miRNAs. Interaction with Drosha and DGCR8 results in the
cleavage of the pri-miRNA into a shorter ~60-70 nucleotide pre-miRNA. Pre-miRNAs
are exported to the cytoplasm by Exportin-5, where they interact with Dicer and
TRBP2 for further cleavage into ~22 nucleotide mature miRNAs. Each mature miRNA
is estimated to silence the expression of up to 100 target mRNAs.
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4.1.2. The miRNA pathway in Wilms tumor
The miRNA pathway has recently emerged as a critical regulator of
nephrogenesis.17,32 Perturbation of this pathway in specific cell types and precise
times during renal development results in abnormal renal morphogenesis and cancer.
Indeed, mutations in components of the miRNA pathway have recently been identified
in a subset of Wilms tumors. Exome sequencing of poor outcome Wilms tumors, as
well as high-risk blastemal Wilms tumors revealed heterozygous mutations in
DROSHA and DGCR8 in 15% of these selected tumors. Heterozygous mutations in
the RNase IIIb domain of DROSHA have been found in ~12% of favorable histology
Wilms tumors.16 In the majority of DROSHA-mutant tumors, a recurrent mutation
(E1147K) affecting a metal ion binding residue of the RNase IIIb domain was found.
These somatic mutations act through a dominant-negative mechanism to impair
processing of primary miRNAs, resulting in the reduction of global miRNA
biogenesis.16-17,32 Gene and miRNA expression profiling has demonstrated that the
miR-200 family is one of the subsets of miRNAs reduced in tumors, correlating with
downregulation of genes involved in the mesenchymal to epithelial transition.
Given the multistep progression of miRNA processing, it is not surprising that
other genes involved in the stepwise progression of miRNA biogenesis have also
been found somatically mutated in Wilms tumors. Mutations in DGCR8, a component
of the microprocessor complex and cofactor of DROSHA, as well as XPO5 and
TARBP2 have also recently been identified through next-generation sequencing
efforts.16 Occasionally, mutations in several miRNA pathway genes have been found
in the same tumor providing multiple hits to the miRNA pathway and underscoring the
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importance of a normal functioning miRNA processing system. One component of the
miRNA pathway that is mutated less frequently than DROSHA and DGCR8 is
DICER1.

4.1.3. DICER1 and DICER1 Syndrome
One of the enzymes at the center of the micro RNA biogenesis pathway is
DICER1. Located on chromosome 14q32.13, DICER1 is a large multidomain enzyme
containing twenty-six coding exons (Figure 19). DICER1, functioning downstream of
DROSHA and DGCR8, encodes a cytoplasmic endoribonuclease essential for the
generation of mature microRNAs from pre-miRNAs.88 In order for DICER to perform
its ribonuclease activity, the protein folds such that the RNase IIIa and IIIb domains
form an intramolecular dimer, creating a catalytic core whereby each domain cleaves
one strand of the double-stranded pre-miRNA substrate. The RNase IIIa and IIIb
domains cleave the 3p and 5p miRNA strands, respectively. This requires proper
positioning of the RNA substrate over the catalytic domains, which is accomplished by
a number of DICER domains. Among these are the platform and PAZ domains, which
recognize the 5’ terminal phosphate and 3’ 2-nucleotide overhang of the pre-miRNA,
respectively. Additionally, the DExD/H box helicase domain is thought to form a clawlike structure to clamp down on the loop structure of the substrate, ultimately allowing
correct positioning of the dsRNA along the

connector helix, where a positively

charged surface interacts with the phosphate backbone residues of the pre-miRNA.
Following the favorable interaction between the pre-miRNA and DICER, cleavage of
each strand takes place at a fixed distance from the terminal ends of the pre-miRNA,
generating a mature miRNA of 22 nucleotides.
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Figure 19. DICER1, located on chr14q, contains 27 exons and contains a number of
well characterized domains. Figure modified from Foulkes, Nature Reviews Cancer,
2014.

Dicer1 knockout in the mouse is embryonic lethal, suggesting that loss of
Dicer1 activity is incompatible with normal development. Dicer1 is expressed in the
fetal kidney, where it is critical for renal morphogenesis. Particularly, kidney-specific
ablation of Dicer1 in early metanephric mesenchymal cells results in renal dysgenesis
and apoptosis. These mice show nephron progenitors that are initially correctly
specified with normal ureteric bud outgrowth, however subsequent ureteric branching
and nephron differentiation do not occur.70
Most DICER1 mutations identified in Wilms tumors to date are somatic
alterations, although germline mutations are occasionally observed.89-91 Mutations in
DICER1 were first identified to cause familial pleuropulmonary blastoma in 2009.92
Since then, biallelic mutations have been identified in a variety of tumor types,
including Wilms tumors, which suggests a “two-hit” tumor suppressor model.91 In this
model, germline mutations, frequently truncating, are inherited, whereas somatic
missense mutations occurring at hotspots within the RNase IIIb domain result in a
second hit contributing to the development of a well-defined tumor predisposition
syndrome referred to as DICER1 Syndrome.89 This is a pleotropic cancer syndrome
which commonly includes

phenotypes such as pleuropulmonary blastoma, cystic

nephroma, ovarian sex cord-stromal tumors, and multinodular goiter, as well as less
frequent phenotypes including differentiated thyroid carcinoma, pituitary blastoma,
pineoblastoma, and Wilms tumor, among others. Penetrance of the various
phenotypes of DICER1 Syndrome is incomplete, with more than half of mutation
carriers exhibiting none of the phenotypes associated with the syndrome.
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4.2.

Materials and Methods

4.2.1. WTX593 and WTX279 Families
Following informed consent, blood was drawn and DNA isolated from affected
individuals and/or obligate carriers from 48 WT families. Genomic DNA from two of
these families was then used for whole genome sequencing. These two families did
not carry WT1, WTX, CTNNB1 or TP53 mutations. The first family (WTX593)
consisted of four individuals diagnosed with unilateral WT, with the age of diagnosis
ranging from 38-57 months. Additionally, thyroid colloid cysts, multinodular goiter
(MNG), and kidney multi colloid cysts, and/or pulmonary cysts were noted in family
medical records. Fresh-frozen Wilms tumor was available from one individual.
In the second family (WTX279) two individuals were diagnosed with WT, one at
3.5 years of age and the other at 13 years of age. The latter, the proband, relapsed
after two years and was found by CT scan to have two small pulmonary nodules
which, however, were too small to biopsy. Additionally the father of the proband had
one kidney removed at 3 years of age due to a suspected, but poorly documented,
premalignant condition.
Whole genome sequencing of peripheral blood DNA was carried out on two
affected individuals and one obligate carrier individual in the WTX593 family as
described in chapter 2.

4.2.3. Protein modeling of DICER1 mutation
Protein modeling of the DICER1 G803R mutation was performed using the
Protein
!
!

Homology/analogy

Recognition
!

Engine

version

2.0

(Phyre2;
78!

http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index)

following

the

manufacturer’s instructions.

4.2.4. Mutation analysis of DICER1 in familial Wilms tumor.
Sanger sequencing was performed (as described in chapter 2) to confirm the
DICER1 variant detected by WGS and to assess 47 additional families for mutations
in the same DICER1 exon (exon 15) or seven other DICER1 exons (exons 8, 9, 13,
14, and 24-26) at which mutations have been reported in WT. Primer sequences are
listed in Table 10.
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!DICER1!exon!7!
DICER1!exon!8!
DICER1!exon!9!
DICER1!exon!13!
DICER1!exon!14!
DICER1!exon!15!
DICER1!exon!24!

Forward!primer!
TTCTCACTACTGCAGTATTGATACCTT!
AAATCCCAGTTAAACCCCAC!
TAAATCACCGTCGCCAAATC!
TTTTACTAGGCAGGACTTTTAAAGATG!
TTTGCAGTCCAGCTCATATTG!
CTGAGATCCGCTGACTTAC!
TGTGGGGATAGTGTAAATGCTTC!

DICER1!exons!25@!
26!
TGGACTGCCTGTAAAAGTGG!

Reverse!primer!
GAGCCGCATTAAGCATATTTTC!
TCACATCACAACACAGGACG!
AAATCACTCTACAGCTACCTCATGG!
AAGTGTTCATGGTGCATGATTC!
AAGCTGTGAATCGGAGAAAG!
CCCCTCAAAATTAACAGGTA!
TGCCGTCAGAACTCTGAAAC!

TGAACTTTTCCCCTTTGATG!

Table 10. DICER1 exon primer sequences for Sanger sequencing
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4.3.

RESULTS

4.3.1. Whole genome sequencing identifies DICER1 as candidate predisposition
gene.
Blood DNA from three affected/obligate carrier individuals from the WTX593
family was used for whole genome, paired-end sequencing to identify the Wilms
tumor predisposing alteration in the family (Figure 20a). The mean whole genome
sequencing coverage across all genes for the three individuals sequenced (Figure
20b) ranged from 32-45X, with 97% coverage of genes at >10X depth. Variants
shared by all three individuals were identified and filtered based on their allele
frequency reported in the general population (<1%), with novel variants occurring in
protein coding regions assigned a higher priority for investigation. Of the 113 variants
left after filtering, a novel missense mutation in DICER1 was of greatest interest
because mutations in this gene have recently been found in DICER1 syndrome
families which include a member with WT.16 The identified mutation (c.2407G>A,
chr14:! 95574690, hg19) occurred in exon 15 of DICER1 and results in a glycine to
arginine substitution at codon 803 (G803R) (Figure 21). The variant was not present
in

the

Single

Nucleotide

(http://www.ncbi.nlm.nih.gov/SNP),

Polymorphism
NHLBI

Exome

database
Variant

(dbSNP)
Server

(http://evs.gs.washington.edu/EVS) nor 1000 Genomes database. This alteration was
predicted to be deleterious by SIFT, PolyPhen2 and MutationTaster (0, 0.991, 0.999,
respectively). The mutation occurred at an evolutionary conserved amino acid residue
(PhyloP – 0.999) within the platform domain of DICER1, which is involved in
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Figure 20a. WTX593 pedigree. Of the four unilateral Wilms tumor cases in the family,
blood was obtained from two. Whole genome sequencing (indicated by red boxes)
was performed on these family affected family members (V-1, V-2), as well as an
obligate carrier (II-13)

SUMMARY OF VARIATION
Individual
Gender
Coverage

V-2
Female
44.5

V-1
Male
32.3

III-13
Male
41.5

SNPs
Insertions
Deletions

3,766,935
335,055
350,486

3,683,999
318,537
332,452

3,680,540
317,365
335,863

Shared, Novel Variants
Synonymous SNPs
Nonsynonymous SNPs
Nonsense SNPs
Insertion
Deletion

60
80
1
46
32

Figure 20b. The coverage and total number of variants across the whole genome for
each individual sequences. This includes data for calls where Q score >20.
Additionally, the number of shared, novel exonic variants are listed.
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V-2

V-1

III-13

Figure 21. Next-generation sequenced reads visualized with IGV showing the
DICER1 G803R variant in each family member. The variant is present in ~50% of
sequence reads.
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the recognition of the 5’ phosphate group of pre-miRNAs, and between residues that
interact with the 5' phosphate of miRNAs.21
DICER1 is actively expressed in early renal progenitor cells (Figure 22) and
knockout studies show a failure of nephron differentiation, suggesting DICER1 activity
is required for kidney development.

4.3.2. DICER1 G803R cosegregates within the “DICER1 Syndrome” family
We confirmed the alteration by Sanger sequencing and extended our analysis
to additional family members to estimate the penetrance of the variant in the family. It
was noted that other phenotypes of DICER1 syndrome were present in some family
members. In total, we detected the G803R mutation in eleven family members, some
of whom displayed one or more of the phenotypes associated with familial DICER1
syndrome, including lung cysts, thyroid cysts, MNG, cystic nephroma and WT (Figure
23a).

4.3.3. Loss of wildtype allele observed in tumor
The one tumor available for study was found to be homozygous for the G803R
mutation by Sanger sequencing (Figure 23b). Such homozygosity for a germline
DICER1 mutation has not previously been reported for Wilms tumors, although this
has been observed in cases of DICER1-associated pineoblastoma and pituitary
blastoma.99,100 Typically in Wilms tumors arising in individuals with a DICER1
truncating mutation, somatic hotspot mutations occurring within the RNase IIIb
domain have been described.
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Figure 22. DICER1 expression in the fetal kidney
using gudmap.org. DICER1 is actively expressed in the
metanephric mesenchyme and ureteric bud at E11.5.
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A

B

Figure 23. DICER1 G803R co-segregates with the affected/obligate carrier status
with the family. “+” indicates the individual carriers the G804R variant. “-“ indicates
family members who do not carry the variant. Other DICER1 Syndrome phenotypes
are listed on the pedigree. WT: Wilms tumor, TC: thyroid cysts, MNG: multinodular
goiter, BKT: benign kidney tumor. Sanger sequencing of the only tumor available from
the family shows loss of the wildtype allele.
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3.3.4. Protein modeling of DICER1 mutation suggests a functional effect
Protein modeling using the Protein Homology/analogy Recognition Engine v2.0
(Phyre2; www.sbg.bio.ic.ac.uk/phyre2) suggests that the G803R mutation disrupts an
alpha helix at the end of the platform domain, potentially altering the 5’ terminal
phosphate recognition pocket of the domain (Figure 24). Residues within this pocket,
and adjacent to the G803R variant, interact with the terminal phosphate group on the
5p miRNA strand. This is consistent with the SIFT, PolyPhen and Mutation Taster
scores which predict the substitution of a glycine for an arginine at codon 803 is
deleterious.

Wildtype

G803R

Figure 24. Protein modeling performed in Phyre2. Shown is a protein model of the
platform and PAZ domains of wildtype DICER1 (left) and G803R (right). Highlighted in
blue are the differences between each model, due to the introduction of an arginine
residue at codon 803. This results in the alteration of an alpha-helix within the
platform domain.
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4.3.5. DICER1 mutation analysis in familial Wilms tumor
Sanger sequence analysis of one member each of 47 additional WT families
revealed that one carried a novel frameshift mutation (c.2399delG, p.R800fsX5) in the
same exon (exon 15) as that in WTX593 (Figure 25a). This mutation also occurs in
the evolutionarily conserved platform domain, was not present in the 1000 Genomes
database, dbSNP or the Exome Variant Server, and segregates with the affected
status in the family (Figure 25b). It is predicted to encode a truncated protein lacking
an intact platform domain and the remaining half of the protein, including the PAZ
domain and the RNase IIIa and IIIb domains. Tumor samples were not available for
this family; LOH could not be assessed.
Sanger sequencing of seven other exons in which DICER1 mutations have
been previously identified in WT cases (exons 8, 9, 13, 14, 24, 25, 26) was also
performed in 46 other Wilms tumor families. No germline variants were observed in
these families.
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II-4

II-3

III-3

Figure 25a. Identification of an additional germline DICER1 mutation in a Wilms
tumor family. The variant is a frameshift deletion predicted to result in the premature
truncation of the protein. Sanger sequencing showed the variant segregates with the
affected status in the family.
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4.4.

DISCUSSION

Mutations in miRNA pathway genes have recently been identified in approximately
15% of favorable histology Wilms tumors.17 The majority of these are somatic
mutations

clustering

at

RNase

domains

of

DROSHA

and

DICER1,

two

endoribonucleases critical for proper miRNA maturation. While the vast majority of
these are somatic mutations, germline mutations in DICER1 have been identified in
several tumor types and are associated with a pleiotropic tumor predisposition
syndrome called DICER1 syndrome. In this syndrome, inherited truncating mutations
and somatically acquired missense mutations occurring at or adjacent to metal-ion
binding residues (D1705, D1709, D1713,G1809, E1813) within the RNaseIIIb domain
are typically found in families. The result of these biallelic mutations is impaired 5p
miRNA biogenesis, including major miRNA families such as let-7 and miR-200, while
3p miRNA levels are unaltered. This reduction of 5p miRNAs is thought to contribute
to the development of DICER1-associated phenotypes through the deregulation of
target genes, including members of the miR-200 family with roles in the mesenchymal
to epithelial transition critical for normal kidney development.
To date, only six DICER1 families with a member diagnosed with WT have been
reported in the literature and each of these has only one WT case. In these rare
families, similar to non-WT DICER1 families, germline DICER1 nonsense mutations
were observed, along with an additional somatic missense mutation occurring in trans
in the tumor.16 In our study, we identified two Wilms tumor families with novel germline
DICER1 mutations. Both germline mutations occurred in the platform domain, which
has a role in recognizing the terminal phosphate group of the 5p strand of premiRNAs for correct positioning over the RNase III domains for cleavage (Figure 26).
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Figure 25b. Germline DICER1 mutations found in Wilms tumors. Indicated in
blue are those previously reported, while those in red were identified in our
study.

Previous studies have shown mutations in this domain result in reduced processing
efficiency of mature miRNAs.21 Consistent with what has been observed in other
DICER1 families, the novel mutation (R800Xfs5) we identified in WTX279 is predicted
to result in the premature truncation of the protein. WTX279 is a small WT family, and,
while it is not known whether individuals in this family displayed phenotypes
associated with DICER1 syndrome, pulmonary nodules were detected in the proband
by CT scan. These nodules, however, were too small for biopsy and it is unknown if
they were WT metastases or were similar to the cystic pulmonary phenotype that is
observed in DICER1 Syndrome. Uniquely, multiple family members were diagnosed
with Wilms tumor in this small family; DICER1 families reported to date have only a
single WT case.
The diagnosis, not only of Wilms tumor, but also of MNG, lung cysts, thyroid and
kidney cysts in the WTX593 family is consistent with this being a “DICER1 syndrome
family”. In total, 11 individuals in this family were found to carry the germline mutation,
with 2/11 diagnosed with only WT, 2/11 diagnosed with WT and lung cysts, 2/11 with
thyroid cysts, 1/11 with MNG and 1/11 with kidney cysts. In addition to the presence
of multiple WT cases, WTX593 is unique on several counts. First, it carries a germline
DICER1 missense mutation rather than a frameshift or nonsense mutation. Only one
other family (in which only multiple nodular goiters are observed) is reported to have
sustained a germline missense mutation. Interestingly, this mutation (Ser839Phe) also
occurred in the platform domain. The G803R mutation we identified in WTX593 is
predicted to be deleterious by a number of functional prediction algorithms and occurs
at an evolutionarily conserved amino acid residue, suggesting this mutation is
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functionally significant. Moreover, protein modeling suggests this alteration disrupts
an alpha helix in the platform domain.
Secondly, the germline G803R mutation in WTX593 was reduced to homozygosity
in a tumor from a family member. In contrast, almost all the second, somatic
mutations observed in tumors from individuals with germline DICER1 mutations are
missense mutations that occur in the RNase IIIb domain of DICER1. To date, loss of
heterozygosity with retention of the germline mutation has only been reported in two
DICER1-associated phenotypes – pineoblastoma and pituitary blastoma.99,100 LOH
has not previously been reported in Wilms tumors with DICER1 mutations.
Additionally, like WTX279, WTX593 is a family where a germline DICER1 mutation
results in multiple cases of Wilms tumor. The penetrance of the G803R allele with
respect to Wilms tumor is notably much higher than other germline DICER1 mutations
(which, as noted above, are almost invariably truncating mutations). The basis for this
increased penetrance is not known. Obviously, ascertainment bias is a factor as the
families being studied were originally selected due to the occurrence of two or more
Wilms tumor cases. However, is it still curious that families ascertained for PPB and
other, DICER1-associated phenotypes only rarely have a member with Wilms tumor
(much less two or more), while in both families reported here, the DICER1 mutations
were relatively highly penetrant with respect to Wilms tumor.
Interestingly, while the penetrance of the two novel DICER1 mutations we
identified in these two families was unusually high, the ages at which individuals in
these families were diagnosed with Wilms tumor was notably older than average
Wilms tumor cases in general. The median age of diagnosis for unilateral Wilms
tumor overall is ~39 months of age while that of unilateral cases in familial context is
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35 months. Wilms tumor families, however, greatly vary with respect to age at
diagnosis, with some families exhibiting typically younger ages, while other families
consist of cases with later than average ages of onset. The observation that both
families carrying DICER1 mutation reported here have members diagnosed at late
ages suggests that this may be a common feature of DICER1-related Wilms tumor.
Our data demonstrates that mutation of DICER1 is associated with the
development of familial Wilms tumor and describes interesting and novel findings with
respect to the missense mutation we identified. Our identification of germline DICER1
mutations in 4% of Wilms tumor families is consistent with the recent reports
describing mutations in multiple members of the miRNA biogenesis pathway in
sporadic Wilms tumors.
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CHAPTER 5: Identification of a recurrent 570kb duplication on chr2p
encompassing NBAS, DDX1, MYCN and MYCNOS in Wilms tumor
families.
5.1.

INTRODUCTION
Copy number variation of specific regions of the genome have been identified

in sporadic Wilms tumors using array comparative genomic hybridization (aCGH) and
SNP arrays.93 These include losses at 17p, 1p, 16q and gains at 1q, 8, 12, suggesting
that these regions harbor genes that play a role in Wilms tumorigenesis. After
sequencing the whole genome of two individuals from a large Wilms tumor family, we
detected a 570kb duplication on chr2p24 which predisposes to the development of
Wilms tumor. This region includes 4 genes; NBAS, DDX1, MYCN and MYCNOS, and
was initially selected for further investigation due to the established role of MYCN in
both development and Wilms tumorigenesis.

5.1.1. MYCN functional activity and it’s role in kidney development
MYCN belongs to the MYC family of transcription factors with well-documented
roles in the control of cell proliferation and differentiation.94 MYCN is a conserved
basic helix loop helix transcription factor that forms a heterodimeric complex with Max
and binds to a CANNTG E-box consensus sequence found upstream of promoter
target sequences. This complex acts as a transcriptional regulator by activating or
repressing hundreds of target genes through the interaction with various nuclear
protein complexes.
MYCN expression, primarily detected in the developing embryo, is absent from
adult tissues suggestive of a principal responsibility in mediating embryonic
development. Indeed, experiments in mice have shown that MYCN is essential for
!
!

!

95!

both neurogenesis and nephrogenesis. Homozygous ablation of MYCN in mice
results in embryonic lethality at E10 due to defects of the central nervous system,
kidney, lung, gut and heart. In the developing brain, MYCN is involved in the induction
of a stem-cell like state by blocking differentiation and activating the pluripotency
factors, KLF2, KL4 and LIN28B. Moreover, reduction of MYCN expression levels in
neuroblastoma cell lines leads to induction of a differentiated phenotype. MYCN is
particularly interesting with respect to Wilms tumor biology, as it is highly expressed at
early stages of development in the metanephric mesenchyme. Its expression
becomes increasingly restricted as embryonic development proceeds and is
undetectable in adult human kidney tissue. Reduced or loss of MYCN expression in
cultured embryonic kidneys results in renal hypoplasia due to a decrease in cell
proliferation in ureteric bud and mesenchymal tissues, while apoptosis was not
affected.38 Thus, MYCN expression in the embryonic kidney is critical for
nephrogenesis.

5.1.2. MYCN alterations in Wilms tumors
5.1.2.1. Amplification
Amplification of one particular region on chromosome 2p24, including the
MYCN locus, has been described in several pediatric cancers, including Wilms
tumor.18,33-36 In 10% of Wilms tumor cases, increased MYCN copy number and
expression has been described, suggesting this region has a functional role in the
development of Wilms tumors. MYCN is also somatically amplified in other childhood
cancers

such

as

neuroblastoma,

medulloblastoma,

retinoblastoma,

alveolar

rhabdomyosarcoma, and astrocytoma. Of these, MYCN has been most extensively
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studied in the context of neuroblastoma, where it is amplified in roughly 25% of cases
and is associated with poor prognosis. In Wilms tumors, somatic MYCN amplification
has primarily been observed in the context of sporadic cases. However, a germline
chr2p24 duplication encompassing MYCN and detected by array comparative
genomic hybridization (aCGH) was reported in one family with a history of
nephroblastomatosis and Wilms tumor.95 This duplication was subsequently observed
in an additional patient with bilateral Wilms tumor from an independent study, as well
as in our analysis (described below).

5.1.2.2.

MYCN is often coamplified with other flanking genes

When MYCN amplification has been observed in both neuroblastoma and
Wilms tumor, it frequently includes additional neighboring gene(s), including orthinine
decarboxylase (ODC), syndecan-1, ribonucleotide reductase (RRM2), ALK, DDX1,
NBAS, and MYCNOS. Genes coamplified with MYCN in Wilms tumor cases include
the 5’ region of NBAS, as well as the complete coding sequences of DDX1 and
MYCNOS. For example, MYCN and DDX1 were both somatically amplified in a Wilms
tumor-derived xenotransplanted cell line.96 Moreover, germline duplication of a 570kb
region including these genes has been recently observed in Wilms tumor patients. To
date, DDX1 amplification without concomitant MYCN amplification has not been
described, suggesting MYCN as the primary gene responsible for tumorigenesis.
Interestingly, a genome-wide association study (GWAS) identified a significant
association signal within this duplicated region when examining 1,488 Wilms tumor
samples.97 Collectively, this suggests germline copy number alterations in this region
could predispose to Wilms tumor.
!
!

!

97!

DDX1, a DEAD box helicase that has roles in the alteration of RNA secondary
structure, is frequently coamplified with MYCN (DDX is 340kb 5’ of MYCN, and is
telomeric of MYCN on 2p24). Like MYCN, DDX1 is also strongly expressed during
early kidney development (Figure 27). A recent report described a nuclear role of
DDX1, where it acts as a cofactor of DROSHA in ovarian cancer cells in the
recruitment of a specific subset of pri-miRNAs for processing.98 This provides an
intriguing connection to the miRNA biogenesis pathway, which has very recently been
implicated in Wilms tumor development.

5.1.2.3. Point mutations
Not only is MYCN amplified in sporadic Wilms tumors, but a somatic
heterozygous point mutation (c.131C>T, p.P44L) within the aurora kinase A domain
has recently been identified in ~4% of Wilms tumors by several groups using nextgeneration sequencing.18 This variant was somatic in all cases and is believed to be a
gain of function mutation due to its occurrence at a highly conserved amino acid
residue. Tumors carrying the P44L mutation do not appear to have morphologically
distinguishing features to suggest the alteration results in a specific histology or
clinical stage. In one study, 40% of P44L-mutant tumors also had modest MYCN
amplification. Interestingly, a bilateral Wilms tumor case described separate MYCN
alterations in one patient: an MYCN point mutation (P44L) in one tumor with MYCN
amplification in the contralateral tumor, suggesting multiple mechanisms of MYCN
dysregulation in Wilms tumor development.18
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Figure 26. Expression of DDX1 and MYCN in the mouse fetal kidney
from gudmap.org. Both are actively expressed throughout early kidney
development, specifically in the metanephric mesenchyme (blue box).
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MYCN

DD1X

5.2.

Materials and Methods

5.2.1. WTX614 and WTX637 families
Following informed consent, blood was drawn and DNA isolated from members
of the WTX614 and WTX637 families. Mutation analysis of WT1, WTX and CTNNB1
revealed no germline mutations in the affected individuals, thus the predisposition
gene mutation was determined to be unknown. The WTX614 family consists of eight
Wilms tumor cases, with the age of diagnosis ranging from 14 to 204 months.
Additional phenotypes in the family included medulloblastoma and astrocytoma.
Tumor samples were not available for these patients for further analysis. The
WTX637 family contained five Wilms tumor cases, with the age of diagnosis ranging
from 5 to 72 months. Tumor samples were also not available from these family
members.
Whole genome sequencing of peripheral blood DNA was carried out on two
affected individuals in the WTX614 family (IV-3 and III-11) as described in chapter 2.
5.2.3. Copy number analysis using qPCR
Copy number variation was confirmed using a SYBR green qPCR assay with
primers targeting DDX1 and MYCN. Primer sequences are listed in Table 11.
Genomic DNA, gene-specific primers and SYBR green were analyzed using the
Applied Biosystems 3730 real time machine. Additionally, primers targeting ** on
chromosome 5 (one of the regions where copy number alterations are rarely observed
in Wilms tumor) served as a control.
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MYCN
DDX1

Forward primer
GAGAGGACACCCTGAGCGATT
CCCAACTGATATCCAGGCTGAA

Reverse primer
CAAGACATACGAGCACTAACAAAGG
AGTGTGTCCCCAGCTACCAATC

TABLE 11. qPCR primer sequences for MYCN and DDX1 copy number analysis.
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5.3.

Results

5.3.1. Whole genome sequencing identifies recurrent 570kb duplication on
chr2p
We sequenced the whole genome of two affected individuals in a large, multigeneration WT family (Figure 27a) consisting of 8 WT cases to identify the
predisposing alterations contributing to the development of FWT. The mean coverage
across the genome was 30X for IV-3 and 33X for III-11, with 96.5% and 96.8% of
positions covered by at least 10X (Figure 27b).

Comparison of shared variants

resulted in the identification of 344 novel, exonic variants (excluding synonymous
variants). These genes were assessed for known developmental or differentiationrelated roles in the embryonic kidney. After surveying single nucleotide variants within
the family, we were not able to identify a convincing candidate gene for further
evaluation. Although several genes appeared to be potential candidates based on our
criteria for identifying predisposition genes, none of them had a clear role in renal
morphogenesis. Next, we examined shared structural variants, including large
insertions, deletions, duplications, inversions and translocation calls generated using
CASAVA v.1.8. This analysis examined read depth to identify regions where copy
number gains or losses were suspected due to read density deviation from the
average coverage calculated across the whole genome. This resulted in the
identification of a 570kb duplication on chromosome 2p24 encompassing 4 genes:
NBAS, DDX1, MYCN and MYCNOS (Figure 28). This duplication was initially selected
for further investigation because MYCN has previously been shown
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A

B
SUMMARY OF VARIATION
Individual
Gender
Coverage

IV-2
Male
33.6

III-11
Male
30.5

SNPs
Insertions
Deletions

3,673,595
315,113
329,229

3,676,171
317,527
327,892

Shared Novel Variants
Synonymous SNPs
Nonsynonymous SNPs
Stop Gain SNPs
Stop Loss SNPs
Insertion
Deletion

83
94
0
0
37
22

Figure 27. WTX614 pedigree. Individuals whose whole genomes were sequenced
are indicated by red boxes. The summary of genetic variation is also listed including
data for calls where Q score >20.

!
!

!

103!

Figure 28. The chr2p24 570kb duplication includes four genes: NBAS, DDX1, MYCN
and MYCNOS. Coverage plots for the boundaries of the duplication are shown from
each individual sequenced. Copy number variation was identified after extracting read
counts for each position across the whole genome, segmentation of the genome into
50bp segments, and calculating read depth within the 50bp segments compared to
average coverage across the whole genome. Regions with increased or decreased
read density compared to the whole genome were classified as gains or losses,
respectively.
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to be amplified in ~10% of Wilms tumors, with germline duplication of this gene
potentially serving as a mechanism for increased expression.
5.3.2. Duplication co-segregates with affected/obligate carrier status
Quantitative PCR (qPCR) was used to confirm the duplication using primers
targeting an exonic region of DDX1 and MYCN. Extending this analysis to additional
family members revealed the duplication segregates with the affected/obligate carrier
status and is absent in all spousal controls tested (Fig29). In total, 9 members of the
family carried the duplication and 7, including 4 spousal controls, did not carry the
duplication. Each affected and obligate carrier individual in the family, for whom we
had blood samples for, carried the duplication. 5 of 9 (55%) carriers developed Wilms
tumor, consistent with the characteristic reduced penetrance of Wilms tumor in
families.
5.3.3. Copy number analysis in familial Wilms tumor identified second family
with co-segregating duplication
Additionally, we assessed this region in one member from each of 47 other WT
families to determine the frequency of the duplication in familial WT (Figure 30). This
analysis resulted in the identification of an additional family (WTX279) that harbors the
570kb duplication. The duplication was found to segregate with the affected/obligate
carrier status in WTX279 and is absent in spousal controls (Fig30). 4/6 (66%) carriers
in the family developed Wilms tumor. In total, we detected this recurrent duplication in
2/47 (4.2%) WT families.
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Figure 29. Copy number was confirmed using qPCR targeting DDX1 and MYCN. The
570kb duplication on chr2p24 cosegregates with the affected/obligate carrier status in
the family. + indicates carriers of the duplication, - indicates those members who don’t
carry the duplication.
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Figure 30. Copy number analysis of DDX1 in one member of 48 Wilms tumor
families identified an additional family with copy number gain of DDX1.
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832066*000BL"
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802830*100BL"
144121*000BL"
832022*000BL"
802500*701BL"
802917*001LC"
802999*000LC"
832063*000LC"
802893*001BL"
832018*001LC"
832053*000LC"
832074*000BL"
802825*000TT2"
802967*005BL"
802864*000LC"
802869*000LC"
802674*000LC"
832098*200BL"
389664*000BL"
802994*000BL"
802951*000BL"
802668*000LC"
832095*000LC"
802614*020"control"
802662*000BL"
007435*000BL"
802826*000LC"
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Figure 31. Copy number was confirmed using qPCR targeting DDX1 and MYCN. The
570kb duplication on chr2p24 cosegregates with the affected/obligate carrier status in
the WTX279 family. + indicates carriers of the duplication, - indicates those members
who don’t carry the duplication.

!
!

!

108!

5.4.

Discussion
This chapter describes two Wilms tumor families with a chr2p microduplication

that cosegregates with the affected/obligate carrier status in each family. The
identification of multiple families harboring this duplication from our study and others,
as well as previous reports of amplification of MYCN in approximately 10% of Wilms
tumors suggests that copy number variation of this region is associated with the
development of Wilms tumor. Further support comes from recent studies that
described a recurrent MYCN point mutation (P44L) in ~4% of Wilms tumors, which
has also been identified previously in neuroblastoma. This somatic recurrent mutation,
occurring at a highly conserved residue, has been suggested to be an activating
mutation, although studies have not functionally validated its significance. It is likely
that an activating mutation in MYCN could have the same functional effect as MYCN
amplification on downstream targets. Interestingly, this recurrent point mutation
occurs within the aurora kinase A interaction domain which, when bound to MYCN, is
involved in insulating MYCN from FBXW7-mediated degradation. FBXW7, an element
of an E3 ubiquitin ligase complex involved in the direct targeting of MYCN for
ubiquitylation and proteasome-mediated degradation, is

somatically mutated in

approximately 4% of Wilms tumors. Therefore, gain of MYCN or the loss of genes
involved in it’s regulation (FBXW7) potentially have overlapping downstream functions
allowing exploitation during kidney development to give rise to Wilms tumors.
Interestingly, alterations in MYCN copy number have previously been found in
other childhood cancers in addition to Wilms tumor. These include retinoblastoma,
neuroblastoma, astrocytoma, and medulloblastoma, where MYCN gain is associated
with an adverse outcome. In the WTX614 family, two individuals carrying the
!
!

!

109!

duplication were also diagnosed with medulloblastoma and astrocytoma. There has
been

no

evidence

reported

previously

suggesting

a

germline

duplication

encompassing DDX1 and MYCN predisposes to these tumor types. However, two
reports have described somatic amplification of this region in both medulloblastoma
and astrocytoma tumors, although this appears to be a rare event. While
constitutional MYCN duplications have been found to predispose individuals to
neuroblastoma, none of the patients in this study who carry the germline duplication,
to our knowledge, developed neuroblastoma.
The mechanism of the reduced penetrance in these families is not known, and
tumor tissue was unavailable from both families carrying the germline duplication,
eliminating the possibility of molecular analysis of tumors for additional alterations.
Intriguingly, a patient carrying a germline partial 2p trisomy including MYCN
developed a neuroblastoma with dramatic amplification of MYCN, suggesting the
germline duplication might predispose to further somatic amplification. While we can’t
rule out this scenario in the Wilms tumor patients from our study, a recent report
describing a bilateral Wilms tumor patient carrying this chr2p germline duplication
showed no further amplification of MYCN in the tumor sample. Another possibility for
the reduced penetrance is that, while the chr2p duplication predisposes to Wilms
tumor, additional mutation events at other loci have to occur during the progression of
tumorigenesis. A previous report described a bilateral Wilms case in which one tumor
contained an MYCN P44L mutation and TP53 V173L mutation, whereas the
contralateral tumor contained MYCN amplification and a different TP53 mutation
(I195T).18 This depicts a situation where MYCN amplification or mutation might not be
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sufficient for tumor development without an additional mutation event occurring before
or after MYCN alteration.
Collectively, these data suggests that a constitutional chr2p duplication
predisposes to Wilms tumor and patients carrying this duplication are at increased risk
of developing Wilms tumor. Additionally, children with germline duplications of genes
within this region potentially are at risk for the development of other tumors types,
such as medulloblastoma and astrocytoma, although more studies are needed for
definitive proof. The finding that MYCN might predispose to other tumor types in
addition to Wilms tumor suggests that therapies targeting the MYCN pathway might
be of significant value in other tumors as well.
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CHAPTER 6: Summary and Future Directions
6.1.

Summary of Data
The etiology of Wilms tumor is genetically heterogeneous. Like sporadic Wilms

tumor cases, the genes and associated pathways contributing to familial Wilms tumor
initiation and progression are diverse. The recent advancements in next-generation
sequencing technologies have provided investigators with a high-throughput tool to
investigate the genetic landscape of Wilms tumor, providing a glimpse into the
complexity of the genetics of this childhood cancer. The research presented in this
thesis is a perfect example of the characteristic genetically heterogeneous nature of
Wilms tumor.
Whole genome sequencing was performed using blood DNA from members of
three Wilms tumor families. Bioinformatic filtering within each family identified shared
variants for further consideration as candidate predisposition genes. DNA samples
from an additional 45 Wilms tumor families were then analyzed for mutations in these
candidate predisposition genes. Our analysis resulted in the successful identification
of Wilms tumor predisposition genes in each family.
We identified DICER1 exon 15 germline mutations in 2/48 (4%) Wilms tumor
families. These novel mutations occurred at evolutionarily conserved amino acid
residues within the DICER1 platform domain and were predicted to be deleterious.
Interestingly, there were multiple cases of Wilms tumor within each family, which has
not been observed in DICER1-associated Wilms tumors to date. Loss of the wildtype
allele in one tumor was also an additional novel finding. Our data provides support
that mutations in the miRNA biogenesis machinery can give rise to familial Wilms
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tumors and is consistent with recent reports describing alteration of these genes in
Wilms tumor.
We also identified a germline 570kb duplication on chr2p24 in 2/48 (4%) Wilms
tumor families. This duplication encompasses NBAS, DDX1, MYCN and MYCNOS.
This duplication was previously observed in members of a multigenerational Wilms
tumor family, as well as in a blood sample from a patient with bilateral Wilms tumor.
MYCN and DDX1 amplification have been associated with sporadic Wilms tumors and
our data reinforces the involvement of these genes in Wilms tumor development. We
also observed other phenotypes, in addition to Wilms tumor, in members of the
families that carry this duplication. As a result, this duplication might increase the risk
of medulloblastoma and astrocytoma as well.
Finally, we identified SPHK2 as a 19q candidate predisposition gene. The
SPHK2 mutation we identified cosegregates in a large Wilms tumor family, has not
been reported in variant databases, occurs at an evolutionarily conserved amino acid
residue, and is functionally significant. This mutation alters SPHK2 subcellular
localization and expression of target genes in MCF7 and M15 cell lines. Mutations
identified in other Wilms tumor families and sporadic tumors provides additional
evidence implicating this gene in familial Wilms tumor predisposition. Significantly, the
identification of SPHK2 mutations in Wilms tumors opens up new avenues of research
into how altered sphingolipid metabolism and signaling contribute to Wilms tumor
development. Our data represents a significant advancement in understanding the
etiology of familial Wilms tumor and associates alteration of new pathways with Wilms
tumor development.
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6.2.

Future directions of research
The first step in understanding the mechanism of Wilms tumor development is

to identify genes responsible for its formation. The goal of the research presented in
this Thesis was to expand the etiology of Wilms tumor occurring in families, thus
making a significant contribution to our understanding of cancer development in
families. The next step will be to build on the novel findings presented here, in order to
learn more about nephrogenesis, identify how these genes and their associated
pathways contribute to aberrant differentiation and tumor formation, and recognize
potential therapeutic targets.
DICER1 has been previously associated with Wilms tumor development in the
context of DICER1 Syndrome, and progress is currently being made to understand its
role, as well as that of the other miRNA biogenesis genes, in relation to Wilms tumor
development. Potential future areas of research include characterization of the G803R
mutation with respect to tumor formation. Possible experiments could include
transfecting a kidney cell line with DICER1 wildtype and mutant constructs, followed
by a miRNA cleavage assay and miRNA expression profiling to determine which
miRNAs are deregulated. This would provide clues as to which genes are important in
Wilms tumor development.
Recent studies are starting to uncover the significance of MYCN alterations in
Wilms tumors and the mechanisms whereby they contribute to cancer. Interestingly,
our data suggests that another gene within the duplicated region shared by affected
family members might also contribute to Wilms tumor. DDX1 was recently shown to
interact with Drosha and DGCR8, where it recruits specific subsets of pri-miRNAs for
processing. Future research could focus on the specific pri-miRNAs that DDX1 binds
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to, in order to 1) determine if DDX1 has a functional effect on Wilms tumor
development and is not just amplified due to the proximity of MYCN, and 2) determine
potential genes regulated by the DDX1-specific subset of miRNAs.
SPHK2 has never been implicated in Wilms tumor development. Consequently,
how this gene functions with respect to kidney development and initiation of
tumorigenesis is unknown, although our data and others have started to suggest a
role in regulation of gene expression. Future research using mouse models could
focus on how SPHK2 contributes to development of the embryonic kidney, as well as
how mutating SPHK2 results in Wilms tumors. Specifically, introduction of
SPHK2R101W into the mouse will provide a more complete picture of the involvement of
SPHK2 in Wilms tumor development. Also, SPHK2 has not been extensively
characterized and comparison of the SPHK2 amino acid sequence to other proteins
has failed to identify functional domains. Future areas of research focusing on a
comprehensive characterization of SPHK2 would greatly facilitate research into its
functions. Additionally, further characterization of the known functions of SPHK2
would clarify the apparent discrepancies reported in the literature with respect to
localization, impact on proliferation and apoptosis.
Finally, our whole genome sequencing analysis revealed the predisposing
alterations in a small fraction of Wilms tumor families in our cohort. Whole genome or
exome sequencing in other families will no doubt uncover other novel and unexpected
causal genes.
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